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ABSTRACT OF DISSERTATION 
A NOVEL ROLE FOR THE TUMOR-SUPPRESSOR PAR-4 IN REGULATION 
OF ADIPOGENESIS AND OBESITY  
Prostate Apoptosis Response-4 (Par-4) is a conserved and ubiquitous 
tumor-suppressor factor which can selectively induce apoptosis in tumor 
cells, while leaving normal cells unaffected.  While Par-4 is well established 
as a tumor-suppressor, there have yet been no formal investigations as to 
whether it has a physiologic role in normal tissues. 
Early observations of Par-4 knockout mouse lines yielded that the adult mice 
displayed significant weight gain and fat accumulation compared to their wild-
type counterparts while on a conventional chow diet.  Interestingly, obese mouse 
and human subjects were found to exhibit reduced expression of Par-4 in 
adipose tissue as well as lower levels of secreted Par-4 in their plasma, 
compared to samples collected from lean human subjects.   
Subsequent in vitro experiments would show that loss of Par-4 has significant 
impact upon adipogenesis.  Mechanistically, Par-4 loss during adipogenesis in 
cell culture correlated inversely with expression of the adipogenic transcription 
factor PPARγ.  Subsequent experiments would demonstrate that Par-4 
transcriptionally represses PPARγ at the promoter level. 
Thereby, we conclude that Par-4 regulates adipogenesis and lipid accumulation 
through transcriptional repression of the PPARγ promoter.  This research utilizes 
novel models and may be used as the basis for Par-4-mediated therapies for 
obesity and metabolic disease. 
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CHAPTER ONE: INTRODUCTION 
It has been nearly a century since Otto Warburg and colleagues published their 
observations regarding dysregulated metabolic activity in carcinoma cells.  They 
found that tumor cells utilize inordinate amounts of glucose and ferment this 
glucose to lactate regardless of oxygen availability.  This ‘aerobic glycolysis’ was 
the first major connection between altered metabolic states and cancer (Liu et al., 
2010).   Whilst most subsequent studies focused upon glucose/lactate 
conversion, attention would later be directed to the role played by fatty acid 
metabolism and obesity.  Several types of tumor cells display accelerated 
lipogenesis (Furuta, Okuda, Kobayashi, & Watabe, 2010) and fatty acid oxidation 
(Carracedo, Cantley, & Pandolfi, 2013). 
Besides the changes in fatty- acid metabolism, obesity is linked with several 
types of cancer, including liver, esophageal, colon, post-menopausal breast 
carcinoma and possibly that of the prostate (Kelesidis, Kelesidis, & Mantzoros, 
2006).  Some hypothesized mechanisms include increased acid reflux 
contributing to esophageal cancer (Q. Chen, Zhuang, & Liu, 2012) or chronic 
inflammation promoting liver cancer (Sun & Karin, 2012).  However, other 
possible mechanisms may involve changes to insulin signaling or the tumor 
microenvironment through interactions with adipose tissue.   One significant 
conceptual shift in adipose biology is the modern understanding that adipose 
tissue should not merely be considered a passive reservoir for energy storage, 
but rather can be described as an endocrine organ in its own right (Huerta, 
2006).  Adipose tissue secretes important regulatory hormones like leptin and 
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adiponectin (Q. Chen et al., 2012), as well as inflammatory mediators like TNFα 
or IL-6 (Sewter, Digby, Blows, Prins, & O’Rahilly, 1999).  Further: adipose tissue 
can act upon proximal tumors in a paracrine manner  to influence growth or 
invasive potential (Wolfson, Eades, & Zhou, 2015) (Dirat et al., 2011). 
Furthermore, phenotypic changes observed amongst tumor-associated 
adipocytes indicate crosstalk between breast tumors and proximal adipocytes.  In 
vitro experiments demonstrate that breast cancer cells co-cultured with 
adipocytes can stimulate de-lipidization of the adjacent adipocytes, and utilize the 
newly-freed free-fatty-acids to support proliferation and invasion  of the tumor 
cells (Balaban et al., 2017; Laurent et al., 2017).   
With all this in mind, it should not be surprising that cellular metabolism can be 
affected by altered expression of oncogenes or tumor-suppressor genes- such as 
Ras, Myc, (Liu et al., 2010) (Faubert et al., 2013) or p53 (Liang, Liu, & Feng, 
2013).  This can also be extended to obesity or generation of fat cells 
(adipogenesis).  As one pertinent example: p53 can suppress transcription of 
genes required for lipogenic enzymes (Yahagi et al., 2003), can inhibit adipocyte 
differentiation (Molchadsky et al., 2013) and inhibits high-fat diet- induced weight 
gain in mice (Wang, Zhao, Gao, Mei, & Wu, 2013).   
As our group focuses upon the tumor-suppressor Prostate Apoptosis Response-
4 (Par-4), we undertook a series of studies to determine whether Par-4 might 
possess a physiologic regulatory role distinct from its known tumor-suppressor 
functionality.  Long-term observations of whole-body-Par-4 knockout mouse lines 
yielded that the adult mice displayed significant weight gain and fat accumulation 
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(as well as numerous physiologic hallmarks of obesity), compared to their wild-
type counterparts while on a conventional chow diet.  This obese phenotype was 
recapitulated in an adipocyte-specific Par-4 knockout mouse model.  Subsequent 
in vitro experiments would show that loss of Par-4 has a significant impact upon 
adipogenesis.  Mechanistically, we found through Western blotting that Par-4 
loss correlated inversely with protein expression of the adipogenic transcription 
factor PPARγ in both in vitro and in vivo models.  Refining our model, a 
combination of qPCR, luciferase reporter assays and chromatin 
immunoprecipitation experiments would demonstrate that Par-4 transcriptionally 
represses PPARγ at the promoter level.  Conversely, we also found that obese 
human subjects were found to exhibit reduced expression of Par-4 in adipose 
tissue as well as lower levels of secreted Par-4 in their plasma, compared to 
samples collected from lean human subjects.  Similar results were observed in 
dietary obese mice.  Based on our experimental data, I hypothesize that Par-4 
regulates adipogenesis and lipid accumulation through transcriptional repression 
of the PPARγ promoter.  These findings are significant as they describe a tumor 
suppressor which acts as a novel regulatory factor for adipogenesis and obesity, 
as well as a novel regulatory factor for PPARγ.  Furthermore, these experiments 
demonstrate reduced expression and secretion of a tumor suppressor (Par-4) by 
obesity.  This suggests that loss of Par-4 is a possible contributing factor in 
tumorigenesis or tumor progression in obese subjects.  I further posit that a 
future benefit of this research would be the development of Par-4-mediated 
therapies for obesity and metabolic diseases. 
4 
Prostate Apoptosis Response-4 (Par-4) 
The Par-4 (PAWR) gene (Figure 1.1) encodes a ubiquitously expressed tumor 
suppressor protein which can induce apoptosis via an array of intrinsic or 
extrinsic pathways.  A particular point of therapeutic interest is the novel finding 
that Par-4 can be secreted by normal cells under conditions of endoplasmic 
reticulum (ER) stress, inhibition of autophagy as well as p53 activation and 
inhibition of NF-κB.  This secreted Par-4 can then selectively induce apoptosis in 
tumor cells in a paracrine or possibly autocrine manner, while leaving normal or 
immortalized cells unaffected (Burikhanov et al., 2009). The discovery of Par-4 
was borne out of an effort to identify therapeutically exploitable tumor suppressor 
genes.  The laboratory of Vivek Rangnekar at the University of Kentucky 
performed differential hybridization experiments on cDNA from the AT-3 
androgen-independent prostate cancer cell line after treatment with the Ca2+ 
ionophore ionomycin.  This experiment resulted in the induction of an early 
apoptotic response gene (designated Par-4).  Further experiments yielded that 
Par-4 gene expression is upregulated in rat prostatic cells in response to 
androgen deprivation and that Par-4 is not upregulated by growth stimulation, 
growth arrest or necrosis.  These results demonstrated that Par-4 is an 
apoptosis-associated gene or tumor suppressor (Sells et al., 1994).  Clinical 
evidence of Par-4’s status as a tumor suppressor can be gleaned from the 
findings that Par-4 has been shown to be downregulated or mutated in renal cell 
carcinoma, neuroblastoma, endometrial and breast cancer (Cook et al., 
1999)(Shrestha-Bhattarai & Rangnekar, 2010).  Additional studies have 
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demonstrated that reduced Par-4 expression and activity correlates with 
unfavorable chemotherapeutic treatment prognosis and reduced radiosensitivity 
of breast and colon tumors (Alvarez et al., 2013; Contract, Mackley, & Irby, 2011; 
Pereira et al., 2013).  
Par-4 structure 
Par-4 is not only ubiquitously expressed across tissues but is found in a wide 
range of vertebrates, ranging from humans, mice and pigs to fish, birds and frogs 
(Nadia El-Guendy & Rangnekar, 2003).  Par-4 is ordinarily translated in the 
cytosol in normal cells, but under conditions of ER stress or in tumor cells, Par-4 
can be translated by ribosomes in the ER.  Par-4 has also been observed to 
display a high degree of homology within the nucleic acid and peptide sequences 
between species.  For simplicity’s sake, we shall focus here on the human, rat 
and mouse Par-4 peptide sequences, which are approximately 40kDa and 340 
amino acids (AA) long in humans, 332 AA in rats and 333 AA in mice.  Similarly, 
Par-4 possesses a number of 100% sequence conserved functional domains 
(Figure 1.2).  These domains include (in order from amino terminal to carboxy-
terminal): two putative nuclear localization sequences (NLS1 and NLS2) the 
"Selective for Apoptosis of Cancer Cells" (SAC) domain, a C-terminal leucine 
zipper (LZ) domain and a C-terminal nuclear export sequence (Shrestha-
Bhattarai & Rangnekar, 2010).  Additionally, the localization and activity of Par-4 
can be affected by the phosphorylation status of certain conserved residues by 
the kinases ζPKC, PKA (at Thr 155 in rats, Thr 163 in humans) and AKT (Ser 
249 in rats, Ser 228 in humans) (Shrestha-Bhattarai & Rangnekar, 2010).  NLS1 
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is only six AA in length, and oddly, deletion of this domain does not prevent Par-
4’s nuclear entry, downstream activity (eg: preventing NF-κB transcriptional 
activity) or apoptosis, rendering NLS1’s function to be unknown at this time. 
NLS2, by contrast is 17 AA long, and had been found to be essential for 
translocation of Par-4 from the cytoplasm to the nucleus.  It has been shown that 
deletion of NLS2 will prevent nuclear entry, changes to NF-κB transcriptional 
activity and apoptosis (Nadia El-Guendy, Zhao, Gurumurthy, Burikhanov, & 
Rangnekar, 2003). 
The SAC domain was identified through a series of structure-function 
experiments performed by El-Guendy et al. to establish the functions of Par-4’s 
domains.  Deletion analysis of rat Par-4 yielded a 59 AA core domain 
encompassing amino acids 137-195, which was found to represent the minimal 
functional domain which would selectively induce apoptosis in cancer cells.  This 
study as well as later ones would find that Par-4 mediated apoptosis is 
predicated upon its NLS2-mediated nuclear entry as well as phosphorylation of 
the T155 residue (rat Par-4) by cAMP (Gurumurthy, Goswami, Vasudevan, & 
Rangnekar, 2005).  As it happens: the SAC domain contains both NLS2 and 
T155 (T155 in rats, T156 in mice, and T163 in humans), thus rendering the SAC 
domain as a prerequisite for Par-4-mediated apoptosis.  As will be mentioned 
shortly, the SAC domain also contains the binding region for the chaperone 
protein GRP-78, and is thus vital for extracellular-Par-4-mediated apoptotic 
activity.  As further evidence of SAC’s relevance to cancer: Zhao et al. generated 
mice which overexpress a GFP-tagged SAC domain.  The resulting animals were 
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normal in all major respects, but the animals exhibited a high degree of 
resistance to spontaneous or induced tumorigenesis or experimental metastasis 
(Zhao et al., 2007, 2011). This series of experiments suggest a potential 
therapeutic role for Par-4 or SAC in the future. 
The 41 AA, C-terminal leucine zipper domain is not essential for apoptosis.  
However, it is responsible for a number of Par-4-protein interactions which 
conspire to sensitize a cell for apoptosis (Nadia El-Guendy et al., 2003).  The LZ 
domain of Par-4 interacts with zinc finger domains of such proteins as Wilms’ 
tumor protein (WT-1) (Johnstone et al., 1996) ζPKC (Nadia El-Guendy et al., 
2003), p62 and topoisomerase 1 (TOPO-1)(Goswami et al., 2008).  Some of 
these interactions indicate that Par-4’s LZ can sensitize cells to apoptotic 
pathways and also negatively regulate pro-survival pathways through interactions 
with such factors as TOPO-1, WT-1 and / or ζPKC.  The LZ may also contain a 
nuclear exclusion sequence, causing Par-4 to be generally localized to the 
cytoplasm. 
Par-4 -mediated apoptosis 
Intracellular Par-4- mediated apoptotic activity requires nuclear translocation and 
inhibition of NF-κB (N. El-Guendy, Zhao, Gurumurthy, Burikhanov, & Rangnekar, 
2003).   This downregulation of NF-κB is founded on the observations that Par-4 
can bind the atypical protein kinase ζPKC (Díaz-Meco et al., 1996).  This ζPKC is 
otherwise capable of phosphorylating and tagging the inhibitory IκB peptide for 
proteosomal degradation. It has been further shown that NF-κB transcriptional 
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activity is inhibited by Par-4 phosphorylation by ζPKC (Moscat, Rennert, & Diaz-
Meco, 2006).  
Experiments on the apoptosis of prostate cancer cells by El-Guendy, et.al 
demonstrated that apoptosis is preceded by migration of Par-4 from the 
cytoplasmic compartment to the nucleus.   Later immunoprecipitation 
experiments would show that the AKT1 kinase associates with Par-4 (Goswami 
et al., 2005).  When AKT phosphorylates rat Par4 at S249 (S228 human), this 
promotes binding to the chaperone protein 14-3-3, causing cytoplasmic 
sequestration of Par-4 (Brunet et al., 1999) and subsequently preventing 
apoptosis (Sledziona & Rangnekar, 2017) (Figure 1.3 A). 
Interestingly, Par-4 can also act through extrinsic apoptotic pathways.  For 
example: Par-4 stimulates translocation of surface death receptors Fas/CD95 
and Fas ligand (FasL) to the cell surface (Chakraborty, Qiu, Vasudevan, & 
Rangnekar, 2001).  The Fas-mediated apoptotic pathway can then proceed via a 
caspase-8 dependent manner (Beere, 2005). 
One particularly novel feature of Par-4 is the discovery that Par-4 can be 
secreted into the extracellular environment under conditions of endoplasmic 
reticulum (ER) stress (Burikhanov et al., 2009), p53 activation (Burikhanov et al., 
2014) or inhibition of NF-κB (Burikhanov et al., 2013).  Further: this secreted Par-
4 is capable of subsequent, cancer cell-selective induction of apoptosis in a 
paracrine or autocrine manner.  This discovery has profound implications for 
enhancing current standard-of-care cancer therapies.  
9 
A series of salient experiments by Burikhanov et al. demonstrated that not only 
could Par-4 be secreted after treatment with tunicamycin (an ER stressing 
agent), but eventually that transferring conditioned media (CM) from tunicamycin 
treated cells to untreated cell populations will selectively induce apoptosis in PC-
3 cancer cells, while leaving normal or immortalized BPH-1 cells unaffected 
(Burikhanov et al., 2009).  This property of the CM was found to be abrogated 
through preapplication of Brefeldin A (an inhibitor of the classical ER-to-golgi 
body secretory pathway) to the treated cells.  The apoptotic effect of the CM was 
neutralized through pre-incubation with Anti-Par-4 antibodies- verifying that this 
apoptotic activity was Par-4 dependent.  
Mechanistically, this behavior was found to be dependent upon the chaperone 
protein GRP-78 (AKA: BiP or Glucose-Related Peptide-78), which is ordinarily 
localized to the ER.  This factor was confirmed as a binding partner of Par-4 
though pulldown experiments, as binding to GST-tagged Par-4 from PC-3 lysates 
(Burikhanov et al., 2009).  Additional studies by this research group found it was 
essential that GRP-78 be present at the cell surface for apoptosis by extracellular 
Par-4, which indicated co-localization of the two peptides. Specifically-it was 
found that GRP-78 binds Par-4 at a the SAC domain.  The Authors posit that 
when Par-4 is bound to surface GRP-78, that GRP-78 recruits the FADD adaptor 
protein, which in-turn activates the Caspase-8 to Caspase-3 cascade as this 
process was found to be activated by extracellular Par-4 (Sledziona & 
Rangnekar, 2017) (Figure 1.4).  Basal cell surface expression of GRP-78 has 
been previously reported to be specific to tumor cells (Arap et al., 2004; Raiter, 
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Yerushalmi, & Hardy, 2014) as a result of endogenous ER stress and is 
consequently thought to be a major mechanism behind the tumor-specific 
apoptotic response of Par-4.  Building upon this, it was previously mentioned that 
extracellular secretion of Par-4 can be induced by NF-κB inhibition or p53 
stabilization.  Yeast-two hybrid and co-IP studies by Burikhanov et al. indicated 
that Par-4 can bind another chaperone protein- UACA (Uveal Autoantigen with 
Coiled-Coil Domains and Ankyrin repeats).  Transcription of UACA is upregulated 
by NF-κB and downregulated by active p53 (Burikhanov et al., 2013, 2014). 
UACA, in turn binds to and sequesters Par-4 and GRP-78 in the cytoplasm, 
thereby modulating Par-4 mediated apoptotic activity (Burikhanov et al., 2013; 
Sledziona & Rangnekar, 2017) (Figure 1.3 B). 
Obesity: a ‘systemic’ problem 
Obesity (abnormal or excessive fat accumulation) is a complex condition, which 
involves multiple organs and tissues normally involved in maintenance of energy 
homeostasis.  Chief amongst these are the adipose tissue (storage), liver (lipid 
biosynthesis, gluconeogenesis), pancreas (glucose homeostasis) and brain 
(feeding and physical activity).  Obesity can involve disrupted feedback between 
these tissues, particularly in chronic cases, ultimately manifesting as metabolic 
syndrome. 
The adipose tissue is of course responsible for the storage of triacylglycerides 
(TAG), and release of free fatty acids (FFA) into circulation.  However, adipose 
tissue expansion also triggers regulatory feedback mechanisms.  Adipocytes 
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express and secrete the hormones leptin and adiponectin.  Leptin acts upon the 
hypothalamus to suppress food intake by stimulating feelings of satiety in the 
individual (Klok, Jakobsdottir, & Drent, 2007).  Circulating leptin is commonly 
increased during obesity, but it appears that the hypothalamus becomes resistant 
to leptin’s effects although the mechanism is under debate (Enriori, Evans, 
Sinnayah, & Cowley, 2006).  Adiponectin, however has more widespread targets.  
The adiponectin receptors (AdipoR1 and AdipoR2) increase glucose uptake of 
target tissues by increasing surface translocation of the glucose transporter 
GLUT4, but also act via the AMPK pathway to increase fatty-acid oxidation 
(Yamauchi et al., 2002).  Adiponectin also possesses anti-inflammatory 
capabilities, as it can inhibit NF-κB activation, thereby reducing expression of 
TNFα, IL6, and increasing IL-10.  Adiponectin expression is reduced in chronic 
obesity (Arita et al., 1999; Asayama et al., 2003), possibly through promoter 
hypermethylation (A. Y. Kim et al., 2015).   
The liver has a vital role in energy homeostasis through storing carbohydrates as 
glycogen, synthesizing glucose via gluconeogenesis and by acting as the primary 
site of lipid biosynthesis (de novo lipogenesis- or DNL).  The liver is also 
responsible for packaging FFA into TAG, which are released into circulation and 
taken up by peripheral tissues like muscle and adipose for energy and storage. 
Altered expression levels of lipogenic enzymes can lead to obesity 
experimentally (Strable & Ntambi, 2010). Also, DNL has been demonstrated to 
be a contributor to fatty liver disease (Sanders & Griffin, 2016). 
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The pancreas regulates glucose homeostasis through secretion of insulin from β-
cells and glucagon from α-cells.  Insulin is secreted in response to feeding or 
elevated plasma glucose and binds its receptor (IR) on most tissues to promote 
translocation of glucose transporters to the plasma membrane (Fu, Gilbert, & Liu, 
2013).  This translocation promotes glucose influx.  Furthermore, insulin strongly 
promotes lipogenesis and DNL is also increased under conditions of insulin 
resistance (Sanders & Griffin, 2016).  Glucagon-secreted in response to low 
blood glucose signals the liver to convert stored glycogen to glucose for release 
(Ramnanan, Edgerton, Kraft, & Cherrington, 2011) (figure 1.5). 
Adipogenesis 
Adipogenesis is the process by which mesenchymal stem cells will differentiate 
into fat storage cells (adipocytes).  These progenitor cells are generally first 
influenced by extracellular signals, which eventually trigger a cascade of 
transcriptional regulatory factors, which then initiate the production of 
downstream effectors.   
Adipogenesis may be divided into two primary stages: commitment and terminal 
differentiation (Cristancho & Lazar, 2011).  The process of commitment is not 
perfectly understood, but appears be regulated by canonical and non-canonical 
Wnt signaling and such possible external influences as the stiffness of the 
extracellular matrix.  Regarding Wnt signaling, generally speaking, the canonical 
Wnt signaling axis of receptor LRP6 and ligand WNT10B suppress adipogenesis 
by inhibiting PPARγ induction (Kawai et al., 2007; Takada, Kouzmenko, & Kato, 
2009), whereas the non-canonical ligand Wnt5B can promote differentiation 
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through suppressing B-catenin translocation, which is requisite for canonical 
signaling (Kanazawa et al., 2005).  The perivascular fibroblasts in the Adipose 
compartment capable of adipogenesis are characterized by CD24+, CD29+, 
CD34+ and SCA1+ (Cristancho & Mitchell, 2011).  In response to adipogenic 
stimuli, these committed white preadipocytes undergo a epigenomic transition. 
This transition  is characterized by induction of the adipogenic master regulator: 
the nuclear receptor Peroxisome Proliferator-Activated Receptor Gamma 
(PPARγ) (Cristancho & Lazar, 2011) (Figure 1.6).  
The process of terminal adipogenesis is marked by growth arrest, morphologic 
changes, and induction of several members of the CCAAT/ enhancer binding 
protein family of transcription factors (C/EBP)- starting with C/EBPβ and C/EBPδ 
(Rosen & Spiegelman, 2000).  In vitro, this is rapidly followed by PPARγ and 
C/EBPα, and followed, in turn by the appearance or upregulation of fatty acid 
synthase (FASN), acetyl CoA carboxylase (ACC), malic enzyme, insulin receptor, 
GLUT4 and fatty acid binding protein adipocyte protein 2 (aP2 / FABP4) (Rosen, 
Walkey, Puigserver, & Spiegelman, 2000).  What essentially develops is a 
transcriptional cascade in which PPARγ and C/EBPα reinforce the expression of 
one another, as the PPARγ promoter contains a C/EBPα binding site, enhancing 
its activity (Lee & Ge, 2014a).  Contrariwise, PPARγ activation increases 
transcription of the C/EBPα gene (Zuo, Qiang, & Farmer, 2006).  Additionally, 
C/EBPα and PPARγ  are often found to be simultaneously bound to the common 
promoters of downstream genes upregulated during adipogenesis- this 
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simultaneous binding may allow synergistic promoter activity. (Madsen, 
Siersbaek, Boergesen, Nielsen, & Mandrup, 2014). 
Experimentally, in vitro adipogeneis experiments are performed utilizing 
committed pre-adipocyte fibroblast lines, such as the 3T3-L1 cell line.  However, 
It’s also possible to use primary mouse embryonic fibroblasts (MEFs) (Ruiz-
Ojeda, Rupérez, Gomez-Llorente, Gil, & Aguilera, 2016).  Both of these models 
were utilized for the adipogenesis experiments detailed in this thesis.  The 
process of terminal differentiation can be accomplished through first growing the 
cells to confluence in order to induce cell growth arrest, followed by addition of a 
combination of insulin supplementation, the elevation of cyclic AMP (cAMP) via 
the phosphodiesterase inhibitor Isobutyl methyl xanthine (IBMX), the 
thiazolidinedione (TZD) PPARγ agonist troglitazone, and the glucocorticoid 
dexamethasone (Dex).  The rate of differentiation can be tracked visually and 
lipid accumulation can be visualized through cell fixation, followed by Oil-red-O 
staining of neutral lipids. 
Stimulation of adipogenesis 
During stimulation of the adipogenic pathway, insulin appears to act through 
cross-reactivity with the IGF-1 receptor- leading to phosphorylation and 
stimulation of Ras and AKT(Xu & Liao, 2004).  AKT can, in turn, phosphorylate 
the FoxO1 transcription factor, inhibiting its activity.  FoxO1 has been previously 
found to inhibit adipogenesis, possibly through promoter inhibition of cell cycle 
inhibitors and other adipogenic genes (Nakae et al., 2003).  Both IGF-1 and 
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insulin signaling also remain significant for maintenance of mature adipose 
tissue.  Adipose tissue-specific knockout of either receptor in mice have been 
found to result in dystrophy of white adipose tissue, coupled with severe diabetes 
and fatty liver. (Boucher et al., 2016).   
Activation of cyclic AMP (cAMP) is also known for its ability to induce and 
enhance adipogenesis (E D. Rosen & Spiegelman, 2000).  Petersen, et. al 
describe interactions with multiple central pathways to stimulate transcriptional 
and cytoskeletal changes.  The Authors detail that as cAMP activates PKA, PKA 
will inhibit Rho kinase activity (which normally suppresses adipogenesis through 
attenuation of the Insulin/ IGF-1pathway).  Further, cAMP appears to bind to a 
specific guanine exchange protein (Epac), which can induce changes to 
cytoskeletal organization, adhesion molecules and extracellular matrix 
interactions through inhibition of Rho kinase characteristic of adipocytes 
(Petersen et al., 2008).  Finally, cAMP stimulates the transcription factor CREB 
(cAMP-response element binding protein), which can promote the transcription of 
the C/EBP’s and PPARγ.  As a side note: although IBMX experimentally 
upregulates cAMP, the actual in vivo stimulus for cAMP elevation is uncertain at 
this point (Petersen et al., 2008; J.-W. Zhang, Klemm, Vinson, & Lane, 2004) 
(Figure 1.7).   
Paradoxically, MAPK can also suppress adipogenesis through inhibitory 
phosphorylation of PPARγ and its heterodimerization companion RXR (Rosen & 
Spiegelman, 2000).   
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The glucocorticoid receptor (GR) does not appear to be an absolute requirement 
for adipogeneis, although administration of Dex can certainly accelerate the 
process in vitro.  A recently published manuscript by Park and Ge indicate that 
Dex upregulates multiple pro-adipogenic genes in early adipogenesis, including: 
C/EBPα, C/EBPβ, C/EBPδ, and PPARγ.  The Authors go on to demonstrate 
through ChIP-Seq that Dex-activated GR directly binds at or near those gene 
loci.  In addition, GR recruits the acetyltransferase p300 (CBP) to C/EBPβ-bound 
enhancer regions- further upregulating  transcription of the C/EBPβ target genes 
(Park & Ge, 2017). 
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) 
The adipogenic master regulator PPARγ is a nuclear hormone receptor and 
transcription factor which is encoded by a gene located on chromosome 6 in 
mice (Chromosome 3 in humans) (“NCBI-Gene-PPARG,” 2017).  This gene is 
responsible for modulating transcription of several genes related to insulin 
response, lipid transport and metabolism and adipogenesis (i.e.: GLUT4, the 
insulin receptor (IR), FABP-4 and Fatty Acid Synthase-FASN); further: mutations 
in PPARγ promote lipodystrophy and hyperinsulinema (Hegele, 2005).  
Structurally, the PPAR family members contain four vital domains (listed N-
terminus to C-terminus): a transactivation  domain called Activation Function 1 
(AF1), a DNA-Binding Domain (DBD), a hinge region and ligand binding domain 
(LBD) (Figure 1.8) (Azhar, 2010).  Upon synthesis,  PPARγ will be shuttled to the 
nucleus (Umemoto & Fujiki, 2012) and heterodimerize with another nuclear 
hormone receptor- the Retinoid X Receptor (RXR) (Rosen et al., 2000).  This 
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assembly binds a DNA promoter response element (PPAR Response Element- 
PPRE) and modulates transcriptional activity.  This assembly can recruit either 
transcriptional coactivator or corepressor factors, and thereby up-or 
downregulate transcripion of the target gene.  However, generally speaking when 
not ligand bound, this assembly will generally act as an repressive complex, but 
will also behave as a  transactivation complex when ligand bound (Choi & 
Bothwell, 2012) (Figure 1.9).  While TZD compounds are quite effective synthetic 
agonists, the actual endogenous ligands of PPARγ are not presently well 
characterized.  Previously hypothesized candidate ligands generally represent a 
series of dietary, free fatty acid derivatives or prostaglandins.  These factors, 
however were later found to exhibit poor binding affinity, low local availability or 
have eluded detection in vivo (Tzameli et al., 2004).  The most effective in vivo 
ligand candidates to date appear to be nitrated lipid compounds such as 
unsaturated fatty acids and arachidonic acid derivatives- which have been 
modified by reactive nitrogenous species.  These molecules may incidentally 
represent a new class of signaling molecules relevant to inflammation and 
cardiovascular disease (Villacorta, Schopfer, Zhang, Freeman, & Chen, 2009).  
However more research will be necessary to determine whether these represent 
the PPARγ ligands responsible for modulating adipogenesis in vivo. 
PPARγ has been found to occur primarily as two isoforms- designated PPARγ1 
and PPARγ2 (Zhu et al., 1995).  These isoforms differ in a few respects.  For 
example: PPARγ1 is encoded by eight exons, whereas PPARγ2 is coded by 
seven.  Although the amino acid sequences encoded by the six C-terminal exons 
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in both isoforms are identical, the PPARγ2 peptide possesses a 30 amino acid 
sequence N-terminal to the ATG site for PPARγ1.  As such, both isoforms begin 
transcription at different promoter sites (Zhu et al., 1995).  Not only do the 
promoter sites differ, but the two isoforms exhibit disparate tissue distribution: 
PPARγ1 is rather widely distributed at a low level of expression but is 
concentrated in insulin-responsive tissues such as skeletal muscle, heart and 
liver.  PPARγ2, by contrast is restricted mostly to adipose tissue (Mukherjee, 
Jow, Croston, & Paterniti, 1997), with some expression observed in liver and 
skeletal muscle (Vidal-Puig et al., 1996).  As the PPARγ1 promoter has been 
observed to contain additional CpG islands, it has been speculated that changes 
in promoter hypermethylation may be responsible for this tissue-specific 
distribution (Zhu et al., 1995). There is also significant chromatin remodeling 
observed in the PPARγ2 promoter in the first few hours of adipogenic stimulation; 
particularly around the promoter regions occupied by C/EBPα,β and PPARγ (Lee 
& Ge, 2014a).  This chromatin remodeling has been found to be dependent on 
cAMP and PKA activity, and addition of IBMX is sufficient for loosening the 
chromatin of the PPARγ2 promoter (Lee & Ge, 2014b).  
PPARγ promotes transcription of many genes related to metabolism, lipogenesis 
and adipogenesis, such as GLUT-4 (Marín-Juez, Diaz, Morata, & Planas, 2013), 
VLDLR (Tao, Aakula, Abumrad, & Hajri, 2010) adiponectin (Iwaki et al., 2003), 
and possibly FASN (as evidenced by promoter binding sites for PPARγ1 and 2 
(“Search ChIP-qPCR Assay FASN,” n.d.)). Also PPARγ2 is capable of enhancing 
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transcription of SREBP1, which is in turn known to transcriptionally upregulate 
FASN (Schadinger, Bucher, Schreiber, & Farmer, 2005). 
While adipose tissue expansion can be manifested through increasing the total 
number of adipocytes (hyperplasia) through adipogenesis, expansion can also 
come about through increasing the size of the individual adipocytes 
(hypertrophy). This in turn could come about through one or more of the following 
processes: de novo lipogenesis, increased lipid uptake and/or reduced lipolysis.   
De novo lipogenesis 
Besides dietary fats, another source of fatty acids in the body is de novo 
lipogenesis the biological synthesis of fatty acid chains from acetyl-CoA.  
Physiologically, this is generally the domain of the liver and dysregulation of this 
process is implicated in fatty liver disease (Sanders & Griffin, 2016).  As it 
happens: adipocytes not only store lipids which have been exported by the liver, 
but also are themselves capable of DNL from the catabolism of glucose, pyruvate 
and glutamine (Collins et al., 2011).  In fact there is some evidence that DNL is 
necessary for the maturation of developing adipocytes (Collins et al., 2011).  This 
regulation may be rather complicated, however, as adipose expression of 
lipogenic enzymes appears to be inversely related to obesity (Collins et al., 
2011), but hepatic DNL can be accelerated in hyperinsulemic subjects (Sanders 
& Griffin, 2016).  This may be explained by the finding that insulin stimulates 
lipogenesis through increased transcription of SREBP1 and FAS through the 
PI3K/ AKT/ mTORC signaling axis (Rui, 2014). 
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PPARγ2 is also capable of inducing lipogenesis in adipocytes and 
experimentally, in liver (Schadinger et al., 2005; Y.-L. Zhang et al., 2006) through 
enhanced expression of SREBP-1, FASN and acetyl Co-A carboxylase member 
(ACC1).  Contrariwise, the products of these DNL pathways can act as ligands 
for PPARγ activation.  A basic pathway is detailed below. 
Sterol-regulatory element binding proteins (SREBPs) are transcription factors 
which bind to sterol-response promoter elements in the nucleus and activate 
transcription of multiple lipogenic genes (Y.-M. Kim et al., 2010). Cytosolic ACC1 
catalyzes the addition of a bicarbonate- derived carboxyl group to acetyl Co-A in 
order to convert this substrate to malonyl CoA as the rate-limiting step for FA 
biosynthesis (Davis, Solbiati, & Cronan, 2000).  The resulting malonyl Co-A 
becomes the substrate for cytosolic FASN, which will then add acetyl Co-A to 
malonyl Co-A (utilizing NADPH) to ultimately synthesize 16C palmitate (J. Chen 
et al., 2016).  ELOVL6 (Fatty acid elongase 6)- will convert palmitate to 18C 
sterate (Matsuzaka & Shimano, 2009). Palmitate and sterate are both saturated 
FA’s, however, SCD1 (Stearoyl Co-A desaturase 1) utilizes NADH to catalyze 
formation of monounsaturated fatty acids (delta-9 cis) from palmitoyl Co-A and 
stearoyl Co-A (Paton & Ntambi, 2009). The newly- synthesized FA’s can be 
coupled to a glycerol backbone derived from glycerol-3-phosphate (G3P) in an 
acylation reaction catalyzed by GPAT (Acyl-CoA:G-3-P acyltransferase), 
generating lysophosphatidic acid (Takeuchi & Reue, 2009).  Subsequent 
acylation reactions to generate diacylglycerol and triglycerol are catalyzed by 
acylglycerolphosphate acyltransferase (AGPAT)- followed by dephosphorylation 
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of phosphatidic acid by Lipin-1 (Reue & Dwyer, 2009) and diacylglycerol 
acyltransferase (DGAT), respectively (Yen et al., 2008) (Figure 1.10). 
Lipolysis and β-oxidation 
Obviously, as white adipocytes function as storage vessels for TAG, excess 
adipose TAG accumulation leads to obesity and associated metabolic disorders.  
As a requisite for the mobilization of the stored lipids, the stored TAG’s are 
hydrolyzed sequentially back into free fatty acids and glycerol (Ahmadian, Wang, 
& Sul, 2010; Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E., & Sul, 
2007).  Lipolysis is accomplished by a series of lipases and hydrolases, such as 
hormone-sensitive lipase (HSL), which responds positively to β-adrenergic 
agonists or ACTH and also responds negatively to insulin (Kraemer & Shen, 
2002).  Additional catabolic enzymes include adipose triglyceride lipase 
(Desnutrin) and triacylglycerol hydrolases.  Finally, fatty acid transport out of the 
cell is accomplished through binding with the chaperone protein adipose fatty 
acid binding protein (FABP/aP2). (Duncan, R. E., Ahmadian, M., Jaworski, K., 
Sarkadi-Nagy, E., & Sul, 2007).   
Ironically, obesity is associated with increased basal lipolysis, although β-
aderengic stimulated lipolysis is decreased (Duncan, R. E., Ahmadian, M., 
Jaworski, K., Sarkadi-Nagy, E., & Sul, 2007).  Insulin receptor activation inhibits 
adipocyte lipolysis. Consequently, loss of insulin sensitivity (for example, as a 
consequence of obesity) will fail to impede lipolysis.  It is further believed that 
TNFα, which is often increased in obese adipose tissue can decrease perilipin 
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expression (see next paragraph) and thereby allow accelerated basal lipolysis 
(Ahmadian et al., 2010; Cawthorn & Sethi, 2008). 
The main lipid droplet in adipocytes is protected from lipase activity by being 
covered with the perilipin family of proteins.  When perilipin is phosphorylated by 
PKA as a consequence of β-Adrenergic receptor activation, it alters its 
confirmation to allow exposure of the droplets to lipases.  Insulin, however 
counters this activity by PI3K/ AKT stimulation, which dephosphorylates cAMP 
and thereby inhibits the PKA-mediated phosphorylation of perilipin and HSL 
(Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E., & Sul, 2007).  
FFAs are released from the adipocytes and transported through the bloodstream 
whilst bound to serum albumin proteins.  Glycerol is exported via aquaporins like 
AQP7 into circulation.  This glycerol can be transported back to the liver to be 
utilized for gluconeogenesis or re-esterified to fatty-acyl CoA to fuel TG 
biosynthesis (Rui, 2014).  After circulating FFAs reach their target cells, they 
enter the cells with the aid of lipid transporters like FATP1 (SLC27A1) or CD36 
(Martin et al., 2000; Wu et al., 2006). the FFA's then undergo β-oxidation in order 
to be catabolized into Acetyl-CoA subunits to be fed into the TCA cycle and 
subsequent oxidative phosphorylation (or be shunted from the TCA cycle into 
other biosynthetic pathways).  The enzyme carnitine palmitoyltransferase 1 
(CPT1), located on the outer mitochondrial membrane binds long-chain fatty 
acid-CoA to carnitine, whereupon this molecule is translocated into the 
mitochondrial matrix whereupon, CPT2 cleaves off acyl-CoA and carnitine (Wakil 
& Abu-Elheiga, 2009). There is an additional form of regulation at the level of 
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CPT1;  another related carboxylase enzyme (Acetyl-coenzyme A carboxylase 2- 
ACC2), converts acetyl-CoA to malonyl-CoA at the mitochondrial membrane, 
which inhibits CPT1 and prevents β-oxidation (Wakil & Abu-Elheiga, 2009) 
(Figure 1.11).    
Obesity, inflammation and insulin resistance  
In obese subjects, one observes increased adipose turnover and release of lipids 
which are immunogenic in nature (Iyengar, Gucalp, Dannenberg, & Hudis, 2016).  
As adipose tissue expands beyond the ability of the circulatory system to support 
it, the adipocytes are prone to hypoxic stress.  Furthermore, increased FFA 
levels in adipocytes are linked to ER stress, leading to cell death.  This cell stress 
and death promotes macrophage infiltration into the adipose tissue and triggers 
release of immunogenic factors such as TNFα and IL-6 by the adipocytes as well 
as the macrophages (Cawthorn & Sethi, 2008; Iyengar et al., 2016).  The 
released FFAs are also be taken up by infiltrating macrophages- causing them to 
become foam cells.  FFAs also activate the toll-like receptor family member TLR4 
on the macrophage surface, triggering expression of TNFα and IL-1β, further 
exacerbating the inflammatory response (Iyengar et al., 2016).  Adipocytes have 
also been found to release Monocyte Chemoattractant Protein (MCP-1) 
coincident with increasing adipodosity.  MCP-1 can then recruit monocytes like 
macrophages, as well as neutrophils and lymphocytes (Deshmane, Kremlev, 
Amini, & Sawaya, 2009).  This immunogenic environment promotes loss of 
insulin sensitivity, perhaps leading to type-2 diabetes (Shoelson, Lee, & Goldfine, 
2006).  Although the mechanism is unclear, TNFα reduces transcription of the 
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insulin receptor substrate protein IRS1 and GLUT4 and thereby reduces insulin 
sensitivity of the tissues (Stephens, Lee, & Pilch, 1997).  This reduced insulin 
sensitivity thereby necessitates insulin hypersecretion by the β-cells.  Over the 
long term however, chronic inflammation can lead to β-cell dysfunction and 
failure (Prentki & Nolan, 2006). 
Excessive adipodosity also affects the liver. Excessive triglyceride storage in 
hepatocytes observed during non-alcoholic fatty liver disease in humans is 
sourced from a combination of the adipose tissue (60%), DNL (26%) and diet 
(15%) Lipids released from the adipose tissue can circulate back to the liver and 
accumulate there.  The circulating inflammatory cytokines produced during 
obesity also act systemically and might affect the liver, reducing insulin 
sensitivity.  Even in an insulin resistant state, insulin will continue to trigger 
hepatic DNL (Haas, Francque, & Staels, 2016) (Figure 1.12). 
It has also been well established that obesity increases the likelihood of 
developing cancer, in addition to less favorable treatment prognoses. Cancer 
associated adipocytes display an activated phenotype, characterized by 
increased expression of TNFα, IL-1, IL-6 and matrix metalloproteases (MMPs)- 
which promote invasion (Dirat et al., 2011).  The tumor may also benefit from the 
readily available fatty acids for catabolism and anabolism (Hoy, Balaban, & 
Saunders, 2017; Wen et al., 2017). 
Given otherwise equivalent caloric intake and physical activity, normal weight 
/adiposity is dependent upon a balance between adipogenesis, lipogenesis and 
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lipolysis.  This research tract will describe our observations of the effects of the 
Par-4 tumor suppressor upon these pathways, which together describe a novel 












Figure 1.2: Functional domains of human, rat and mouse Par-4  
The functional domains of Par-4 are highly conserved.  This diagram shows the 
two Nuclear Localization Sequences (NLS1, and NLS2), the SAC domain, and 
Leucine Zipper (LZ). 





    
 
 
Figure 1.3: Regulation of Par-4 by the PI3K/AKT pathway.   
Phosphorylation of Par-4 by AKT promotes binding with 14-3-3, and promoties 
cytoplasmic sequestration (A). 
Par-4 secretion can be promoted by p53 upregulation or NF-κB inhibition, 
through inhibition of NF-κB-mediated transcription of UACA.  UACA ordinarily 
binds Par-4 and prevents it from secretion (B). 




           
 
Figure 1.4: Extrinsic apoptosis pathway as mediated by Par-4.   
Par-4 and GRP-78 can be associated  in the ER (A), however they can be 
localized to the plasma membrane via the classic secretory pathway (B).  Par-4 
can then be released into the surrounding media.  This circulating Par-4 can bind 
to surface GRP-78 (C), and initiate a FAS-like apoptotic caspase cascade (D).  






Figure 1.5: Signaling and fatty acid transport between the Adipose tissue, 
pancreas, muscle, and brain  
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Figure 1.6: Wnt signaling in pre-adipocyte commitment. 
Canonical Wnt signaling (Wnt10b/LRP6) axis (A) enhances β-Catenin signaling, 
which in turn downregulates C/EBPα /PPARγ transcriptional activity.  By contrast, 
the non-canonical Wnt signaling pathway enhances pre-adipocyte commitment 
by inhibiting β-Catenin signaling (B), and in-turn permitting C/EBPα /PPARγ 




       
 
Figure 1.7: Stimulation of adipogenesis 
Stimulation of adipogenesis involves multiple signaling pathways.  Vitally, under 
these conditions, the insulin/IGF-1 axis can stimulate cell-cycle inhibition (A). 
cAMP signaling acts through multiple axes to stimulate transcription of target 
genes (B).  The transcription factors C/EBPα and PPARγ can promote 
transcription of each other and also produce the genes necessary for adipocyte 
maturation (C).  This process can be inhibited by external signals for cell growth 









Figure 1.8: PPARγ protein domains 
Human PPARγ domain structure, showing the AF1 transactivation domain, DNA 
binding domain (DBD), hinge domain and ligand binding domain (LBD).  PPARγ2 
is 30AA longer than PPARγ1 as it differs at the first exon due to alternative 
splicing.  
Amino acid positions from (Azhar, 2010). 
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Figure 1.9: PPARγ Activity 
PPARγ can act as both a transcriptional co-repressor and co-activator. PPARγ 
heterodimerizes with RXR at PPAR response elements at the promoter for target 
genes and can complex with corepressor (A) or coactivator elements (B) 
depending on whether a ligand is bound to the complex. 
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Figure 1.10:  Pathways of de novo lipogenesis. 
Acetyl CoA can be generated as the end product of glycolysis or the derived from 
the TCA cycle (A).  It can be used as a raw material for cholesterol biosynthesis 
(B), as well as generating fatty acids (C).  These fatty acids can be joined 
sequentially with G3P to form phosphatidic acid, DAG and TAG (D). 
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Figure 1.11: Lipolysis, FFA circulation and β-oxidation 
The central lipid droplet of adipocytes is protected by Perilipin proteins, which 
can be activated through phosphorylation and allow access to lipases (A).  The 
cleaved FA are transported out of the cell and enter the circulation (bound to 
albumin proteins) (B).  The target cells uptake FA through transport proteins like 
CD36, transported to the mitochondria and metabolized (C).  Also, note how 
cytosolic ACC1 generates malonyl-CoA for FAs to be utilized for β-oxidation, 
whereas ACC2 on the mitochondrial membrane generates malonyl-CoA to block 
β-oxidation (D). 
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Figure 1.12: Obesity, inflammation and insulin resistance crosstalk 
Adipose tissue in obese subjects (A) releases immunogenic factors which 
stimulate macrophages (B).  This can affect the function of the liver (C), the 
peripheral tissues (D) and the pancreas (E). 
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Project Objectives: 
Par-4 has been previously well established and examined as a tumor 
suppressor.  In this dissertation, I set out to investigate potential physiologic 
functions for Par-4 in normal animals.  Preliminary observations indicated that 
Par-4 knockout mice are significantly overweight compared to wild-type controls.  
This dissertation will describe my phenotypic observations and the findings of 
functional studies that investigate the hypothesis that Par-4 regulates key genes 
involved in lipid accumulation and/or adipogenesis.  These observations are 
significant as they describe a novel regulatory role for Par-4, with implications for 
future research into obesity-associated tumor promotion and its suppression by 
Par-4. 
The following specific aims were pursued:
1. To determine the physiologic function(s) of Par-4 in normal mice
2. To determine the clinical relevance of the phenotype associated with Par-
4 loss
3. To identify the mechanism by which Par-4 loss causes the observed
phenotype through cell culture and mouse models
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CHAPTER TWO: THE PAR-4 TUMOR SUPPRESSOR INHIBITS 
ADIPOGENESIS AND OBESITY VIA TRANSCRIPTIONAL REPRESSION OF 
PPARγ 
INTRODUCTION 
Par-4 is a highly conserved, ubiquitously expressed tumor suppressor protein, 
found in multiple cellular compartments- including the cytosol, endoplasmic 
reticulum and nucleus (Burikhanov et al., 2009; Chaudhry, Singh, Parent, & 
Asselin, 2012; Nadia El-Guendy et al., 2003).  Par-4 can be secreted by normal 
or tumor cells and this secreted Par-4 is capable of selectively inducing apoptotic 
activity on tumor cells via a paracrine or autocrine pathway (Burikhanov et al., 
2009). Par-4 is capable of interacting with such diverse proteins as WT-1, 
GRP78 and ζPKC.  Furthermore, Par-4 has been previously shown to affect 
transcription of certain genes, such as inhibition of Bcl-2 through binding the 
Wilm’s tumor protein WT-1 (Cheema et al., 2003).   
Although previous studies have firmly established Par-4 as a tumor suppressor 
protein, there is little data available at this point which assign broader 
physiological functions to Par-4. Given the ubiquity of Par-4, combined with its 
capability for multiple protein-protein interactions and transcriptional regulatory 
capability, we hypothesized that Par-4 possesses a broader physiologic role.  To 
this end, we undertook a long-term study comparing growth rates of Par-4 wild-
type and Par-4 knockout mice.  The purpose of this dissertation is to detail our 
process and our findings. 
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We compared morphologic and phenotypic characteristics for Par-4 constitutive 
whole-body knockout mice to age-matched wild-type control animals and found 
the knockout animals to be of significantly greater mass compared to controls.  
Further investigation found the knockout mice to be carrying far greater fat mass, 
with several other markers for chronic obesity and insulin insensitivity likewise 
observed.  A series of in vitro experiments demonstrated that Par-4 can inhibit 
the differentiation of primary and immortalized mouse fibroblasts into adipocytes 
and that conversely, expression of Par-4 would be inhibited during adipogenesis. 
In vivo studies utilizing tissues harvested from obese humans and dietary obese 
mice indicate downregulation of Par-4 expression and secretion in obese 
subjects.  These findings provide interesting implications for generation of obesity 
as well as obesity-associated cancer. 
Mechanistically, we have been able to narrow down the myriad of potential 
pathways involved by comparing next-gen RNAseq data from the liver tissue 
obtained from Par-4 wild-type and Par-4 knockout mice.  Western blotting for 
candidate factors prompted us to focus upon elevated expression of the 
transcription factor Peroxisome-Proliferator-Activated Receptor γ (PPARγ) under 
conditions of Par-4 depletion.  PPARγ is a master regulator of adipogenesis and 
is critical for this pathway.  A series of quantitative, real-time PCR (qPCR), 
luciferase reporter assays and chromatin immunoprecipitation experiments 
prompted me to ascribe these effects upon adipogenesis to transcriptional 
repression of the PPARγ2 promoter by Par-4.   
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MATERIALS AND METHODS 
Animal experiments 
Whole- body Par-4 knockout mice were generated as follows: C57BL/6 
background floxed Par-4 mice (designated Par-4fl/fl) were developed by Taconic 
Biosciences.  These mice contain loxP sites flanking the second exon of Par-4.  
These animals would be crossed with a ROSA-26 Cre recombinase mouse. 
After genotyping the resulting offspring, the heterozygous offspring (designated 
Par-4+/-) would be crossed, so that a number of the resulting offspring will have 
exon 2 of Par-4 excised in both alleles (designated Par-4-/-) (Figure 2.1 A).  All 
offspring were genotyped before use (Figure 2.1 B).  Western blotting of the 
spleen, liver, lung, kidney and MEFs have been used to verify that tissue 
expression of Par-4 is knocked-out (Figure 2.1 C). 
Adipocyte-specific conditional Par-4 knockout mice were generated as follows: 
Par-4fl/fl mice were crossed with mice containing a Cre recombinase gene 
controlled by an adiponectin promoter (designated Ad-Cre), obtained from 
Jackson Labs (Figure 2.2).  After genotyping the offspring, heterozygous 
offspring would be crossed, so that a number of the resulting offspring will have 
exon 2 of Par-4 excised (designated Par-4/AKO) in the adipocytes.  
Energy expenditure and body composition 
Two-month old experimental mice were housed in individual metabolic cages.  A 
TSE Labmaster indirect calorimetry system (TSE-systems Inc.; Chesterfield, MO) 
was used to simultaneously quantify energy expenditure, energy intake and 
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locomotor activity.  Whole-body composition parameters (total body fat, lean 
body mass, body fluids and total body water, were measured using an EchoMRI-
100 Body Composition Analyzer unit (EchoMRI; Houston, TX).  The metabolic 
cages and EchoMRI equipment were located at the University of Kentucky 
Center of Research in Obesity and Cardiovascular Disease, supported by an 
Institutional Development Award (IDeA) from the National Institute of General 
Medical Sciences of the National Institutes of Health under grant number 
P20GM103527. 
Oral Glucose Tolerance Tests (OGTT) and plasma insulin measurements 
After six hours of fasting, experimental mice would have blood collected and 
tested via tail-vein bleeding immediately prior to administration of 2g/kg glucose 
as a 25% glucose solution via oral gavage (Time= 0 minutes).  Blood glucose 
was measured using a TRUEresult glucometer (Trividia Health; Ft. Lauderdale, 
FL).  Additional blood glucose measurements were obtained at 15, 30, 60 and 
120 minutes post-glucose administration.   
At each timepoint, blood aliquots would be obtained with heparinized capillary 
tubes and stored in 1.5 ml tubes containing 5 µl of 10% sodium citrate solution on 
ice, which are centrifuged to extract the plasma fraction.  Plasma insulin levels 
for each timepoint were measured using a mouse ultrasensitive ELISA kit (Alpco; 
Salem, NH) according to manufacturer's instructions.  ELISA plate readings of 
OD450 nm were obtained using a Spectramax M2 plate reader, running Softmax 
Pro 5.4.3 and standardized to a 5-parameter logistic curve. 
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All animals were housed in the University of Kentucky Animal facility and all 
experiments were conducted under an Institutional Animal Care and Use 
Committee-approved protocol in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals.  
Analysis of plasma lipid levels 
Measurements of plasma triglycerides (TG) and total cholesterol were conducted 
through use of enzymatic colorimetric assays.  TG levels were determined by 
measuring degradation of plasma glycerol by glycerol kinase and glycerol-3-
phosphate oxidase after hydrolysis of TG to glycerol and fatty acids (GPO-
HMMPS).  Cholesterol levels were determined by measuring degradation of 
cholesterol by cholesterol ester hydrolylase.  Both kits were supplied by Wako 
Diagnostics; Mountain View, CA, and assays were performed according to 
manufacturer’s instructions. Analysis for both lipid tests was based upon OD600
nm, subtracting OD700 nm (reference wavelength values), and fit to a 5-point 
standard curve.  
Cell culture 
Primary Mouse Embryonic Fibroblasts (MEFs) were obtained from Par-4+/+ and 
Par-4-/-mouse embryos at embryonic day 13 and maintained in Dulbecco's 
Modification of Eagle's Medium (DMEM) (Mediatech, Inc.; Manassas, VA) 
supplemented with 10% Fetal Bovine Serum (DMEM+10% FBS), (Sigma Aldrich; 
St. Louis, MO). 
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Short-hairpin RNA mediated knockdown of Par-4 was performed as follows: Par-
4 sh-RNA and control sh-RNA were inserted into a pLKO.1 vector, which was in 
turn packaged into lentiviral particles for delivery.  The sh-RNA genes were 
transduced into A549 and Hop92 human lung cancer cells from ATCC, cultured 
in RPMI (Mediatech, Inc.; Manassas, VA) +10%FBS, and selected under 3μg/ml 
puromycin (Sigma Aldrich).   
Adenovirus-mediated Par-4 expression experiments were performed as follows: 
GFP-Par-4 and control GFP DNA sequences were inserted into a pCMV-Ad5 
vector, which was in turn packaged into adenoviral particles for amplification and 
delivery.  Par-4-GFP fusion and GFP control genes were transduced into 3T3-L1 
cells, cultured in DMEM +10%FBS. 
Adipocyte differentiation 
Differentiation of adipocytes from MEFs was adapted from a protocol provided by 
Fei, et.al (2011)(Fei, Bera, Liu, Xiang, & Pastan, 2011). Briefly:  MEFs would be 
grown in 6-well plates under DMEM+10% FBS.  Once the cells are two days 
post-confluence, the media would be replaced with adipocyte differentiation 
media (vis: DMEM+10% FBS further supplemented with 10µg/ml bovine insulin, 
10 µM troglitazone, 500 µM 3-isobutyl-1-methylxanthine (IBMX), and 1 µM 
dexamethasone).  Cells would be maintained under differentiation media for 8-10 
days, with media replaced every 48 hours.  Insulin, troglitazone, IBMX and 
dexamethasone were all obtained from Sigma Aldrich. 
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Differentiation of adipocytes from 3T3-L1 was adapted from a protocol provided 
by Beibei Zhu at the University of Kentucky.  3T3-L1 cells would be grown until 
48 hours post-confluence in DMEM+10% FBS.  At this time, the media would be 
replaced with media supplemented with 3% FBS, 10µg/ml bovine insulin, 500µM 
IBMX, 10µM troglitazone, 1µM dexemethosone for three days.  After these three 
days, this media was replaced by media supplemented with 3% FBS, 10µg/ml 
bovine insulin and 1µM dexemethosone for six days, with media replaced every 
48 hours. 
Oil red O staining of cultured cells 
At time of Oil Red O (ORO) staining, media would be drawn off from culture 
wells, and wells washed with PBS.  Cells were fixed in 10% formalin for 30 
minutes, and then washed again with PBS.  Oil red O stain (Sigma Aldrich), was 
dissolved in isopropanol and water, filtered and applied to cells for 20 minutes. 
At the end of the staining period, the wells were washed with 50% isopropanol, 
followed with ddH2O.  The wells were then be counterstained with Hematoxylin 
(Sigma Aldrich) for 1 minute, and then washed with ddH2O. 
siRNA knockdown 
siRNA transfections were performed in six-well plates according to manufacturer 
instructions.  Briefly, 3T3-L1 cells were plated 24 hours prior to transfections at a 
density of 106 cells/well.  At time of transfection for each well, 1 μg siRNA duplex 
constructs would be combined with DharmaFECT 1 transfection reagent (GE Life 
Sciences) in a volume of 200 µl serum and antibiotic-free DMEM and allowed to 
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complex for 25 minutes.  siRNA/ DharmaFECT complexes were added to each 
well in serum-free DMEM and permitted to transfect for five hours prior to 
replacing media with 10% FBS- supplemented DMEM.  siRNA constructs for Par-
4 and PPARγ as well as control constructs siRNA A and siRNA B were obtained 
from Santa Cruz Biotechnology; Dallas, TX.  Transfected 3T3-L1 cells were used 
for experiments 48-72 hours post-transfection. 
Real-time qPCR 
Total RNA was extracted from MEFs using an RNeasy Plus mini kit (QIAGEN; 
Valencia, CA).  cDNA synthesis was performed using an iScript DNA synthesis 
kit (Bio-Rad; Hercules, CA).  Analysis of gene expression was performed in 96 
well plates on a Biorad CFX96 touch Real-Time thermocycler and iQ SYBR 
green supermix (BioRad). Samples were run in triplicate and normalized to 
GAPDH.  Total RNA was extracted from adipose tissue using an RNeasy lipid 
tissue mini kit (QIAGEN).  qPCR of human adipose cDNA was performed using 
an ABI 7900HT (Applied biosystems; Foster City, CA).  The following primers 
(Table 2.1) for mouse PPARγ1, PPARγ2, mouse GAPDH, mouse Par-4 and 
human Par-4 were designed using Primer Blast and sourced from Integrated 
DNA Technologies (IDT; Coralville, IA). 
Data were analyzed using the ΔΔCt method relative to GAPDH or 18s controls. 
Next-gen RNA sequencing and data analysis 
Analysis of the transcriptome of Par-4+/+ or Par-4-/- mouse livers was performed 
as follows: Total RNA was extracted from liver tissues from three Par-4+/+ or Par-
47 
4-/- mice using RNeasy mini kit (Qiagen) according to manufacturer’s instructions. 
The RNA-Seq libraries were prepared using TruSeq Stranded Total RNA Sample 
Prep Kit with Ribo-Zero ribosomal RNA depletion (Illumina). The manufacturer’s 
protocols were used to sequence ribosomal RNA-depleted libraries at 2×50-bp 
paired-end reads on an Illumina HiSEq. 2500 in high-output mode, to an average 
depth of 40×106 paired-end reads per sample at the Memorial Sloan Kettering 
Cancer Center. 
For mapping, following data quality assessments, reads derived from residual 
rRNA were removed by aligning (Bowtie2 v2.1.0) against ribosomal RNA 
references derived from Ensembl v74 annotations. The RNA-seq datasets were 
mapped to the target genome using STAR aligner that maps reads genomically 
and resolves reads across splice junctions.  We used the two- pass mapping 
method in which the reads are mapped twice. The first mapping pass uses a list 
of known annotated junctions from Ensembl. Novel junctions found in the first 
pass are then added to the known junctions and a second mapping pass is done. 
After mapping we computed the expression count matrix from the mapped reads 
using HTSeq. The raw count matrix generated by HTSeq was then be processed 
by normalizing the raw gene count based on the total reads for each sample, and 
average gene count for each group was calculated for identifying up-
regulated/down-regulated genes.  Differentially expressed genes were identified 
at a threshold of log2 fold change greater than 0.5. The KEGG Pathway analysis 
and translator tools were also used to place genes in specific pathways. 
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Cloning 
PPARγ2 upstream promoter fragment sequences were amplified from C57/BL6 
mouse genomic DNA , utilizing primers shown in Table 2.2. Amplifed fragments 
were ligated into the MCS region of a pGL4.14 luciferase reporter vector 
(Promega; Madison, WI), and transformed via heat-shock method into DH5α 
chemically-competent E. coli cells (Invitrogen; Carlsbad, CA) using 
manufacturers protocol.  Transformed colonies were selected on ampicillin 
selection plates, expanded as a liquid culture in liquid LBamp media and plasmids 
recovered using a maxiprep kit, following manufacturer’s instructions (Origene; 
Rockville, MD). 
Luciferase expression assay 
Luciferase (luc) reporter assays were performed using a Steady Lite Plus 
reporter gene assay kit (Perkin Elmer, Waltham, MA). Briefly: MEFs or NIH 3T3 
cells were co-transfected with Luc reporter constructs and β-Gal expression 
constructs (in pGL3 vector) in a 96 well plate using Lipofectamine and Plus 
reagent (Invitrogen) according to the manufacturers protocol.  Cell lysates were 
collected 24-48 hours post-transfection in RIPA buffer with appropriate protease 
inhibitors (Roche) for each experimental group, combined with Steady Lite 
reagent and analyzed using a Perkin Elmer TopCount plate reader, with the 
signal normalized to β-Gal expression. 
Immunoblotting 
Protein extracts from cultured cell lysates were prepared by washing cell culture 
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plates in PBS, adding Laemmli buffer and scraping cells into 1.5ml tubes.  
Proteins were denatured by boiling in Laemmli buffer for five minutes. 
Liver tissue lysates were prepared by grinding liver tissue under liquid nitrogen. 
Cell lysis was finalized through addition of RIPA buffer and appropriate protease 
inhibitors (Roche).  Total protein levels were normalized using a Bradford 
colorimetric assay (Biorad), and proteins denatured by boiling for five minutes in 
added Laemmeli buffer.  All lysates were subjected to SDS-PAGE and 
immunoblotting.  Antibodies utilized were Par-4 (R-334), leptin (A-20), 
adiponectin (N-20), GAPDH (Santa Cruz Biotechnology), PPARγ (Cell Signaling 
Technology), and β-actin (Sigma Aldrich).  Band density as measured by pixel 
counts was obtained using Vision WorksLS software by UVP.  
Histology 
White adipose tissue samples were harvested from mice, fixed in formalin for 48 
hours and washed in PBS.  Fixed adipose tissues were embedded in paraffin, 
and sliced into 4um sections.  Hematoxylin / eosin stained adipocyte cross-
sectional area was obtained and determined by area analysis of randomly 
selected adipocytes using ImageJ (NIH).  The average cross-sectional area for 
each tissue group is given in results. 
Freshly harvested liver tissue requiring Oil-red-O staining was embedded in OCT 
embedding compound (Tissue-Tek) and frozen on dry ice.  These cryopreserved 
livers were sectioned, mounted on slides, stained with oil-red-O and 
counterstained with hematoxylin.  Sectioning and staining were carried out by the 
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Markey Cancer Center Biospecimen ond Translational Pathology Shared 
Resource Facility at the University of Kentucky. 
Human adipose and plasma samples from lean and obese adults were provided 
by the Biospecimen and Translational Pathology Shared Resource Facility at the 
University of Kentucky Markey Cancer Center (Grant# P30CA177558).  All 
patient information was anonymized, and all work approved by the University of 
Kentucky institutional review board. 
Chromatin Immunoprecipitation (ChIP) 
ChIP was performed utilizing a ChIP-IT High Sensitivity kit (Active Motif; 
Carlsbad, CA) according to the manufacturer’s instructions.  Briefly: cultured NIH 
3T3 cells (~80% confluency), were fixed in a formaldehyde-containing buffer, 
which would also fix any DNA-binding protein complexes to the chromatin. 
These fixed cells were then lysed by repeated snap-freezing cycles and the 
chromatin sheared via sonication using a Bioruptor Pico device (Diagenode), 
until the resulting chromatin fragment size was approximately 400-500BP.  
Aliquots of recovered sonicated chromatin (15-30μg) was incubated with 4μg of 
relevant antibodies overnight at 4˚C.  The antibody-bound chromatin was pulled-
down using kit-supplied G-protein agarose beads, whereupon the crosslinking 
was reversed, the DNA eluted and subjected to qPCR.  The antibodies used 
were Par-4 (R334) (Santa Cruz), IgG (Santa Cruz)-serving as negative control, 
and C/EBPα (14AA) (Santa Cruz) as positive control.  See Table 2.3 for primer 
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sequences.  ChIP-verified negative and positive control primer sets were 
obtained from Active Motif. 
Statistical analysis 
Results for blood glucose and plasma insulin are expressed as the mean±SEM. 
Results for human adipose tissue Par-4 expression are expressed as mean±SD. 
All other figures are expressed as mean+SEM.   Quantitative data were obtained 
through f-test for variance followed by Student's t test in Microsoft Excel. 
Significance was assumed for P-values <0.05. 
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RESULTS 
Chow-fed Par-4 knockout mice are overweight with increased fat mass 
Although Par-4 has been previously well established as a tumor-suppressor, our 
research group was interested in potential physiologic functions of Par-4.  To that 
end, we had generated constitutive whole-body Par-4 knockout mice (Par-4-/-), 
for which we had maintained observation for 300 days. Our initial cohort used for 
determining the growth rates were comprised of two groups of males (Par-4+/+ 
and Par-4-/-; n=8 mice per group).  Final weights were compiled from a total of 30 
age-matched mice per group. 
An observation which readily became apparent during regular weigh-ins, is that 
the chow-diet-fed Par-4-/- mouse population began to gain weight at a 
significantly greater rate than that of the wild-type controls (Par-4+/+), as shown 
by the divergent weight gain curves (Figure 2.3 A,B).  By the end of the 
observation period (300 days), the mean weight of the Par-4-/- mice was 54g as 
opposed to 32g for the Par-4+/+ animals.  Upon sacrifice and dissection, gross 
anatomic observations yielded that the Par-4 knockout animals displayed greatly 
enlarged gonadal (epidydimal) and subcutaneous fat pads.  EchoMRI analysis 
indicated that fat was responsible for a significantly greater percent of body mass 
in knockout mice.  (Figure 2.3C).  A comparison of organ weights between the 
two populations indicated no significant differences between the mass of the 
heart, spleen or kidneys (kidneys weighed as a pair),  (Figure 2.3D). However, 
the knockout livers were much larger (Figures 2.3 D, 2.4 A), and displayed signs 
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of significant lipid accumulation, as shown by oil red O staining of neutral lipids 
(Figure 2.4 B).   Furthermore, as lipids are synthesized, repackaged and 
processed in the liver, we sought to determine whether plasma lipid levels were 
altered in the Par-4-/- mice.  Results indicate that both plasma triglyceride and 
cholesterol levels were significantly elevated at about 12 months in the Par-4 
knockout mice, compared to age-matched Par-4+/+ controls (Figure 2.4 C).  
As our data indicated increased adipose tissue accumulation between the Par-
4+/+ and Par-4-/- mouse populations, we investigated whether this could be 
attributed primarily to enlargement of the individual adipocytes (hypertrophy) or to 
expansion of the adipocyte population (hyperplasia).  Gonadal fat pads from 
multiple timepoints were fixed in formalin, paraffin embedded, sectioned and H+E 
stained.  Microscopy revealed hypertrophy in the adipocytes of knockout mice as 
young as three months of age.  This observation was recapitulated at 18 months 
of age (Figure 2.5 A,B). 
Continuing our characterization of the obese mice, we characterized the relative 
production of the adipose-specific hormones leptin and adiponectin.  Gonadal 
adipose tissue lysates from the 12 month-old Par-4-/- mice indicated significantly 
elevated leptin (Figure 2.6 A) and reduced adiponectin (Figure 2.6 B) 
expression, compared to Par-4+/+ controls.  
Chow-fed Par-4 knockout mice are hyperinsulinemic 
In order to determine whether glucose homeostasis might be dysregulated, we 
performed OGTT to obtain whole-blood glucose and plasma insulin curves which 
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would show fasting (time=0 on graphs) and post-glucose administration levels.  It 
was found that Par-4-/- mice had blood glucose response curves which were 
comparable to controls, although the fasting glucose was elevated in the Par-4-/- 
animals (Figure 2.7 A).  However, the insulin curves indicate the glucose levels 
were kept in check only though significantly enhanced insulin secretion from the 
pancreas.  This is evidenced by the significantly elevated insulin levels in the 
Par-4-/- mice at all timepoints in the experiment (Figure 2.7 B).   
Par-4 / SAC overexpressing mice weigh less than controls 
Given our observations that Par-4 loss leads to enhanced weight gain, we 
wanted to determine whether overexpression of Par-4 would reduce weight gain.  
For this, we reexamined prior weight data from age-matched mice from an 
earlier, unrelated study.  The animals utilized in this study stably overexpressed 
Par-4, the SAC domain or a GFP control gene in all tissues (see: Introduction, 
pg.6).  We found that the mass of the Par-4 and SAC-overexpressing mice 
weighed significantly less than the GFP control mice (Figure 2.8).  Unfortunately, 
as retrospective data, we could not determine whether this was due to 
differences in the fat content of the animals.  
Par-4-/- mice have an altered metabolic profile 
Use of metabolic cages can generate much useful information regarding the 
mouse metabolic phenotype.   Physical activity levels are measured by mounting 
the cage in an array of infrared (IR) emitters and detectors, which would detect 
movement as the IR beam path is obstructed by the mouse between the emitter 
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and detector. Food and water uptake is monitored by hanging the food/water 
sources on individual load sensors which report removal of the food or water.  
Oxygen consumption (VO2) and CO2 production (VCO2) are determined by 
drawing air samples from the cage at 30 minute intervals, measuring the O2 and 
CO2 levels and comparing those values with those of an unoccupied reference 
cage. This gas data can be used to determine the respiratory exchange ratio 
(RER)- the ratio of VCO2/VO2.  These gas measurements are also utilized to 
calculate the resting and total energy expenditure (REE / TEE).  The REE refers 
to the number of calories required by the body during an inactive 24hour period. 
The TEE refers to the number of calories required by the body during a full 24 
hour period- including active states.  Housing chow-fed Par-4+/+ and Par-4-/- mice 
in metabolic cages revealed several features of the two mouse lines as shown in 
(Figure 2.9).  Firstly, relative to lean mass, there was no observed difference in 
caloric intake between the Par-4+/+ and Par-4-/- mice (Figure 2.9 A), although It 
was observed that the Par-4-/- mice displayed reduced activity during the 
recording phase (Figure 2.9 A).  Paradoxically, however, the Par-4-/- mice also 
recorded elevated total energy expenditure and resting energy expenditure 
(Figure 2.9 B).  We also observed an elevated 24 hour RER in the Par-4-/- 
animals (Figure 2.9 B).  An RER value of 1.0 or more indicates energy source of 
pure carbohydrate, a value of 0.70 indicates one of pure fat, and 0.85 indicates a 
combination of the two. This is because more oxygen is required to oxidize fatty 
acids than glucose (Shmidt-Neilson, 1997). All values obtained for RER are 
between 0.75 and 0.90, thereby the animals are using a mix of the two energy 
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substrates.  However the elevated VCO2/VO2 ratio in the Par-4+/+ mice is 
indicative of a more carbohydrate based energy substrate as opposed to fatty 
acid oxidation based metabolism.   
Par-4 Inhibits adipogenesis in vitro 
In light of the excess adipose tissue development observed in the Par-4 knockout 
mice, we hypothesized that Par-4-depleted fibroblasts may be more likely to 
differentiate into adipocytes.  For our first experiments, we treated post-confluent, 
early-passage (Passage <10) primary MEFs with adipocyte differentiation media 
as described under Materials and Methods.  The plates were fixed, stained with 
oil red O, and scored by manually counting oil red O positive or negative cells in 
five randomly selected fields.  Under these conditions, the Par-4 knockout MEFs 
were far more readily differentiated than wild-type MEFs, as demonstrated 
visually (Figure 2.10 A), and analytically (Figure 2.10 B).  To follow up the 
above results, we examined the adipogenesis trends in a 3T3-L1 pre-adipocyte 
model.  This was done as 3T3-L1 cells represent a standard model for in vitro 
adipogenesis.  To this end, prior to differentiation, we knocked down (KD) Par-4 
and/or PPARγ by transfecting the L1 cells with scrambled control siRNA, Par-4 
siRNA (mouse), PPARγ siRNA (mouse) and lastly: co-transfected Par-4 and  
PPARγ siRNA.  As expected: after differentiation and ORO staining, the Par-4 
KD cells (50% reduction in Par-4 expression) showed significant increases in the 
number of ORO positive cells compared to controls.  By contrast:  the PPARγ KD 
cells (75% reduction in PPARγ expression) displayed a reduction in the number 
of ORO positive cells compared to controls, whereas the combined PPARγ/Par-4 
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KD line was not significantly different from controls.  Western blots for Par-4, 
PPARγ and GAPDH are provided to demonstrate successful knockdown (Figure 
2.11 A).  
Par-4 overexpression inhibits adipogenesis 
As our previous results established that Par-4 knockdown enhances 
adipogenesis in vitro, we decided to investigate whether this effect could be 
neutralized through adenovirus-mediated overexpression of Par-4.  Similar to the 
previous experiment, transfection of 3T3-L1 cells with Par-4 siRNA (generating 
an approximately 30% reduction in Par-4 expression) significantly enhanced 
adipogenesis over cells transfected with control siRNA.  Identical results were 
obtained through transduction of a GFP-control adenovirus to both siRNA 
groups.  However, transduction of a Par-4- containing adenovirus to both siRNA 
groups (control and siPar-4) resulted in significant abrogation of adipogenesis in 
the siPar-4 group and a minor reduction of adipogenesis in the si-control group 
(Figure 2.11 B).  Western blots for Par-4 and GAPDH are provided to 
demonstrate successful knockdown or overexpression.  Note that: adenoviruses 
were administered 24-48 hours after siRNA transfection, and approximately 24 
hours prior to addition of differentiation media to the cells. 
Adipocyte-specific Par-4 knockout generates an obese phenotype 
We have observed that Par-4 loss enhances adipogenesis in vitro and the Par-4 
knockout mice are obese.  We then hypothesized that adipocyte-specific ablation 
of Par-4 would likewise lead to weight gain in vivo, which promped us to examine 
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the same parameters in adipocyte-specific Par-4 knockout mice (Par-4/AKO) as 
we had our Par-4-/- mice.  we have found the Par-4/AKO mice experienced 
significantly greater weight gain by 3-4 months of age compared to the floxed 
control mice (Par-4Fl/Fl).  This trend continued to be observed by 5-6 months of 
age (Figure 2.12 A).  EchoMRI analysis of the six-month mice demonstrated that 
the Par-4/AKO mice had a much-higher percent body fat.  Likewise, dissection of 
the six-month old mice revealed greatly enlarged gonadal and subcutaneous fat 
pads in the Par-4/AKO animals compared to Par-4Fl/Fl controls (Figure 2.12 B).  
Weighing the liver, heart, spleen and kidneys (kidneys weighed as a pair), 
indicated the only significant difference between these organ sets was in liver 
weight (Figure 2.12 C). Furthermore: reminiscent of the Par-4-/- mice, histology 
indicated that the adipocytes of the gonadal fat pads display hypertrophy in the 
adipose Par-4/AKO mice (Figure 2.13).  As an interesting observation, the livers 
in the Par-4/AKO mice were found to be significantly enlarged and oil red O 
stained liver sections displayed signs of fat accumulation.  (Figure 2.14 A).   
However, despite the enhanced adipodosity and fatty livers observed in the 
adipocyte-specific Par-4 knockout mice(Figure 2.14 B), there was no significant 
difference recorded in the plasma triglyceride and cholesterol levels between the 
experimental and control groups (Figure 2.14 C). 
Furthermore, while OGTT indicates Par-4/AKO and control mice have similar 
fasting blood glucose levels (Time=0 on graph), we observe that administration of 
the glucose bolus caused the glucose response curve of Par-4/AKO mice to 
diverge greatly from controls, with mean blood glucose spiking at 400 mg/dl 
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compared to approximately 200mg/dl for the controls.  Ultimately the blood 
glucose levels for both groups return to baseline levels by the 120 minute mark 
(Figure 2.15 A).  Following up with insulin ELISA utilizing the plasma samples 
collected at the OGTT timepoints indicates that like the Par-4-/- mice, Par-4/AKO 
mice are hyperinsulinemic at all timepoints that were tested (Figure 2.15 B). 
Par-4/AKO mice have an altered metabolic profile 
Housing chow-fed control and Par-4/AKO mice in metabolic cages revealed the 
following features of the two mouse lines (Figure 2.16).  Relative to lean mass, 
there was an evident difference in caloric intake between the two lines per 24 
hour period (Figure 2.16 A), seemingly showing increased feeding in the Par-
4/AKO mice. Further, there was no observed difference in activity during the 
recording phase (Figure 2.16 A).  However, the Par-4/AKO mice were recorded 
displaying elevated resting energy expenditure (EE) (Figure 2.16 B).  There was 
also observed an elevated Par-4/AKO 24 hour and resting respiratory exchange 
ratio (RER) (Figure 2.16 B).  The elevated VCO2/VO2 ratio in the Par-4/AKO 
mice is again indicative of a more carbohydrate- based energy substrate as 
opposed to fatty acid oxidation based metabolism. 
Adipogenesis downregulates Par-4 
In the course of the in vitro adipogenesis experiments, I compared Par-4 protein 
expression between simultaneously plated groups of Par-4+/+ MEFs which had or 
had not received the adipocyte differentiation media.  We found that the 
differentiated cells consistently exhibited sharply downregulated Par-4 (Figure 
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2.17).  Thereby, the adipogeneic pathway is capable of rapidly downregulating a 
known tumor suppressor.   
Par-4 is downregulated in obese human subjects 
Given that obesity is linked to tumorigenesis, and Par-4 loss is also linked to 
spontaneous tumorigenesis, coupled with our finding that adipogenesis 
downregulates Par-4, we were intrigued by the possibility that obesity might 
downregulate Par-4 expression.  If verified, this effect would implicate Par-4 
downregulation as a contributory mechanism for obesity-associated 
tumorigenesis.  Taking this further, we could hypothesize that downregulation of 
Par-4 is a prerequisite for adipogenesis and obesity. 
qPCR using primers for human Par-4 and normalizing to amplification of 18S 
revealed significant reduction of Par-4 in the abdominal white adipose tissue 
obtained from 10 obese (BMI≥30) human subjects compared to 10 lean (BMI≤25) 
subjects (Figure 2.18 A). This result was reinforced by a follow-up experiment 
involving an independent cohort of obese and lean human subjects (n=10 in each 
group).  In this experiment, protein lysates (from abdominal white adipose tissue) 
and plasma were obtained from the subjects and subjected to Western blotting, 
probing for Par-4, or GAPDH as a control.  Plasma lysates utilized coomassie-
stained albumin as a loading control.  This indicated that not only was Par-4 
protein expression reduced in obese adipose tissue, but circulating Par-4 levels 
were likewise reduced in 80% of individuals examined (Figure 2.18 B,C).  
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Par-4 is downregulated in dietary-obese mice 
After the observed Par-4 downregulation in obese human subjects, we attempted 
to replicate these findings experimentally.  Specifically, we wanted to determine 
whether obese wild-type mice would exhibit reduced Par-4 levels in body tissues 
and plasma.  the mouse model would also allow us to determine Par-4 levels in 
non-adipose tissues, such as the lung and liver.  We elected to use a dietary 
obesity model, feeding randomly assigned C57/BL/6 wild-type mice either 
exclusively a high-fat diet  (HFD) (60%Kcal from fat), or a control diet (10% Kcal 
from fat).  Mice from both groups were sacrificed after 16 weeks, with tissues and 
plasma harvested.  Adipose, liver and lung tissue was subjected to Western 
blotting for Par4 and GAPDH.  Plasma was probed for Par-4 and albumin used 
as a loading control. 
Weight and body fat content as measured by EchoMRI was significantly elevated 
in the HFD mice from 5 weeks onwards compared to time-matched control-diet 
mice (Figure 2.19 A).  By 16 weeks, Par-4 was found to be markedly 
downregulated in the adipose, liver and lung tissue (Figure 2.19B), as well as 
the plasma of the HFD mice (Figure 2.19C). 
Par-4 regulates genes which promote obesity 
RNAseq was performed on liver RNA due to the liver's heavy role in lipogenesis, 
which would provide the greatest likelihood of finding Par-4 target factors in the 
lipogenic pathway.  RNAseq data is summarized in Table 3.1.  A number of 
62 
genes were found to be upregulated in the Par-4-/- mice which are associated 
with regulation of adipogenesis, lipogenesis, lipid transport and lipolysis.  
PPARγ1 expression is inversely associated with Par-4 status 
Given the established role of PPARγ in adipogenesis and the fact that an obese 
phenotype with significant lipid accumulation are observed in the adipose and 
liver tissues, I decided to investigate whether PPARγ expression could be 
regulated by Par-4.  My initial investigations involved Western blotting of lysates 
for Par-4+/+ and Par-4-/- MEFs, as well as adult mouse (Par-4+/+ and Par-4-/-) lung 
primary fibroblasts and liver lysates, probing for PPARγ and actin.   PPARγ was 
found to be upregulated in all examples of the Par-4-/- samples- at least PPARγ1 
isoform (Figure 2.20 A,B).  To verify this finding wasn’t solely applicable to mice, 
this experiment was repeated using lysates from human lung tumor cell lines 
A549 and HOP92.  These two cell lines had been modified with either a 
scrambled control shRNA construct or a Par-4 shRNA construct, thus generating 
Par-4 knockdown cell lines and selected with puromycin.  Western blotting again 
demonstrated PPARγ upregulation in both A549 Par-4 knockdown (A549 Sh-P4) 
and HOP92 Par-4 Knockdown (HOP92 Sh-P4) lines (Figure 2.20C).  
Collectively, these experiments demonstrate that loss of Par-4 consistently leads 
to the upregulated expression of PPARγ (at least PPARγ1) in mouse and human 
models. 
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Par-4 transcriptionally inhibits PPARγ1 
As we have to this point observed upregulated expression of PPARγ under 
conditions of Par-4 loss or downregulation, we hypothesized that this may be due 
to a transcriptional mechanism as opposed to (for example) 
ubiquitination/proteosomal activity affecting PPARγ at the level of the protein.  
We tested this via real-time qPCR, of cDNA synthesized from the RNA of Par-4+/+ 
and Par-4-/- MEFs, utilizing primers for Par-4, PPARγ1 and GAPDH.  After 
normalizing for GAPDH, we observed significant transcriptional upregulation of 
PPARγ1 in the Par-4 knockout MEFs (Figure 2.21).   
Par-4 overexpression inhibits PPARγ 
Having observed the upregulation of PPARγ under conditions of Par-4 ablation, 
we decided to test whether the opposite may be true, that Par-4 overexpression 
would suppress PPARγ.  Par-4 was overexpressed in 3T3-L1 cells (which were 
found to best tolerate the procedure compared to MEFs) through use of a Par-4 
containing adenovirus.  A GFP construct-containing adenovirus was selected as 
the control.  Lysates were obtained from both groups of transduced cells 48 
hours after infection, and subjected to Western blotting- probing for PPARγ, Par-
4 and GAPDH.  The Par-4-infected fibroblasts were found to express significantly 
less PPARγ1 and PPARγ2 than the GFP-containing cells (Figure 2.22). 
Par-4 inhibits transcriptional activity of the PPARγ2 promoter 
As we’ve demonstrated PPARγ to be transcriptionally repressed by Par-4, it 
would seem that Par-4 is acting as a transcriptional repressor.  Since there is no 
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current evidence that Par-4 is capable of direct DNA binding (there are no basic 
amino acid regions flanking the LZ domain of Par-4), it would appear that Par-4 
may bind another DNA-binding protein and is thereby acting as a transcriptional 
co-repressor.  Our first step towards investigating this is to determine whether 
Par-4 is capable of affecting the activity of the PPARγ promoter.  Given the 
previously observed effects upon adipogenesis, we decided to focus our efforts 
upon the promoter for mouse PPARγ2.  We first generated a series of luciferase 
(luc) constructs (inserted into a pGL4.14 luc reporter vector), using sequences 
from the 3KB region upstream of the start codon (ATG site).  Our initial luc 
constructs included, respectively, the entire 3KB upstream region (Fragment 1/ 
Frag 1), the distal 1.6KB region (Frag 2) and the 1.6KB region proximal to the 
ATG site (Frag 3) (Figure 2.23A).  The sequences for Frag. 2 and Frag. 3 were 
designed to overlap by approximately 260BP to include any sites on the margins 
between the two.  These constructs (as well as an empty pGL4 luc vector 
control) were co-transfected along with a β-Gal expression construct into Par-4+/+ 
and Par-4-/- MEF’s, incubated for 48 hours and subjected to a luciferase 
expression assay and normalized to βGal activity.  Initial results showed that 
luciferase expression and thereby transcriptional activity was enhanced in Par-4-/- 
MEFs transfected with Frag. 1 and Frag. 3.  By contrast, the luciferase activity of 
Frag. 2 is comparable to that of the empty vector control, regardless of Par-4 
status (Figure 2.23B). This indicates that not only does Par-4 status affect 




To further narrow down the promoter region at which Par-4 will affect PPARγ2 
promoter activity, we generated additional luc constructs by designing and 
inserting subfragments of Frag.3’s sequence into the same luc reporter vector as 
before.  These subdivisions were approximately 450BP in length, and overlapped 
the adjacent fragment sequences by approximately 100BP (Figure 2.24 A).  
Utilizing the same luc reporter assay as before in Par-4+/+ and Par-4-/- MEFs, we 
found that Par-4-/- MEFs generated greatly enhanced luc activity (compared to 
Par-4+/+ MEFs) when transfected with a construct containing Frag. 6.  No 
significant difference in activity was observed from the other fragments tested.  
These results indicate that Par-4 acts (directly or indirectly) upon a sequence 
between 580 and 996 bp upstream of the transcription initiation site of the 
PPARγ2 promoter (Figure 2.24 B).  Additional trials (data not shown) 
demonstrated frag 6 would generate luc activity comparable to frag 1 and frag 3.  
Nuclear localization of Par-4 is required for regulation of PPARγ2 promoter 
Given that Par-4 can be found in multiple cellular compartments, we wanted to 
determine whether nuclear localization of Par-4 is required for the previously 
observed effects upon the PPARγ2 promoter.   If true, this would lend credence 
to the hypothesis that Par-4 is acting upon the chromatin.  To accomplish this, I 
made use of  pGL3-based constructs which would contain either a complete 
cDNA clone of rat Par-4 or deletion mutants of rat Par-4 for which either nuclear 
localization sequence had been deleted (designated ΔNLS1 or ΔNLS2).  We 
then then co-transfected each of these constructs (or an empty pGL3 control 
vector) with either Frag.6 or an empty luc vector.  All groups would also be 
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transfected with a β-Gal construct for normalization.  Our intent was to compare 
the effects of transfecting complete Par-4 to ΔNLS1 or ΔNLS2 with regards to 
Frag. 6 luc activity. Proceeding with the luc reporter assay revealed that co-
transfection with the complete Par-4 construct significantly inhibited the luc 
activity from Frag. 6.  This result was replicated by co-transfection with the 
ΔNLS1 mutant, however, co-transfection with the ΔNLS2 mutant completely 
abrogated the effects of Par-4 (Figure 2.25).  Based upon these results, we 
conclude that NLS2 and therefore nuclear localization of Par-4 is required for 
Par-4-mediated regulation of PPARγ2. 
Chromatin Immunoprecipitation indicates Par-4 binds PPARγ2 promoter 
By this point we have established that nuclear entry of Par-4 is a requisite for 
transcriptional repression of the PPARγ2 promoter.  As such, to determine 
whether Par-4 actually binds (directly or indirectly) to the chromatin and thereby 
act as a component of a corepressor complex in this region, we utilized 
chromatin immunoprecipitation (ChIP) analysis.  This would allow us to 
determine whether an anti-Par-4 antibody would pull down the genomic 
sequence region corresponding to Frag. 6. 
For our first trial, we transfected NIH 3T3 cells with either a pGL4.14 control 
vector, a Frag. 6- containing construct or a Frag. 7- containing construct.  As 
previous luc experiments indicated that Frag. 7 does not respond to the presence 
of Par-4 (Figure 2.24 B), we chose to use it as an additional negative control.  
The fixed and fragmented chromatin from all transfection groups was subjected 
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to pull-down with either a Par-4 antibody or IgG control antibody.  The resulting 
ChIP DNA for all groups was subjected to qPCR, utilizing primers specific to 
Frag. 6, Frag. 7 or a negative control primer (designated P6, P7 and NP, 
respectively).  After the qPCR data was normalized to GAPDH in the input DNA 
for all groups, we were able to conclude that the Par-4 antibody but not the IgG 
antibody was able to pull down the sequence corresponding to Frag. 6.  Further, 
the Par-4 antibody did not pull down Frag. 7 (Figure 2.26 A).   
While the previous ChIP experiment demonstrated Par-4 binding to a transfected 
Frag. 6- containing construct, we wanted to conclusively demonstrate that Par-4 
could pull-down the endogenous promoter sequence of interest.  To this end, we 
fixed, recovered and fragmented a larger quantity of native chromatin from NIH 
3T3 cells and performed pull-down with antibodies for Par-4, IgG and C/EBPα.  
The C/EBPα is intended as a positive control as Frag. 6 is predicted to contain a 
putative C/EBPα binding site (“JASPAR 2018,” n.d.).  For the purposes of this 
experiment, qPCR was performed utilizing primers P6 and NP and GAPDH 
positive input control primer pair.  The results again show significant amplification 
of the Frag. 6 sequence in the Par-4 and C/EBPα antibody pull-down groups 
compared to the IgG antibody pull-down group (Figure 2.26 B).  From this we 
can conclude that Par-4 is capable of binding to a chromatin element within a 
specific region of the PPARγ2 promoter sequence under native conditions. 
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Target Fw Primer (5’-3’) Rv Primer (5’-3’) 
Mouse Par-4 AGAATGAAGCTGCGACCCTC ATCTTCTGGGGCACTGGTTG 










Human 18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
Table 2.1: qPCR primers utilized. 
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Fragment Fw Primer (5’-3’) Rv Primer (5’-3’) 
1 GAGTGGTACCGTAAGCAACATTTATTG GAGCCTCGAGAACAGCATAAAACAGAG 
2 GAGTGGTACCGTAAGCAACATTTATTG GCCCCTCGAGTTTAACTTGAATTCTTA 
3 GCCGGGTACCTTTTACATTCTAGACAC GAGCCTCGAGAACAGCATAAAACAGAG 
4 GAGTGGTACCTTTTACATTCTAGACAC GAGCCTCGAGGGTCTAAATATCAGTCA 
5 GAGTGGTACCCATCATTTGGACTACTG GAGCCTCGAGGCCTTTGCCCTTTTTGG 
6 GAGTGGTACCGCTCTTTTAAAGTCCAC GAGCCTCGAGAGGTCCAAAATGTTACT 
7 GAGTGGTACCGATAGATAAACAAATTT GAGCCTCGAGGTACAGTAGTTGGAATT 
7+8 GAGTGGTACCGATAGATAAACAAATTT GAGCCTCGAGAACAGCATAAAACAGAG 
Table 2.2: PPARγ2 upstream promoter sequence primers.  All Fw primers were 
designed to include a Kpn1 restriction site, and all Rv primers include a 
Xho1restriction site.  Primers for fragments 6 and 7 were also utilized for the 




Fw Primer (5’-3’) Rv Primer (5’-3’) 
6 GCTCTTTTAAAGTCCACAAGTCACTG GGAAAACTCTGGCTTCTTGCTTAA 




Primer Set 2 






Proprietary sequence Proprietary sequence 














RGS16 3.823 X Inhibition of β-oxidation 
CD36 2.236 X X X Fatty acid uptake; regulation of lipogenesis and adipogenesis  
ELOVL6 2.181 X Elongation of long-chain fatty acids 
SCD1 2.058 X Synthesis of monosaturated fatty acids 
FASN 1.653 
X 







Synthesis of fatty acid; Inhibition of 
fatty acid and glucose oxidation; 
enhances fat storage 
Lpin1 1.179 
X X 
Synthesis of triglycerides;  
Required for adipogenic gene 
transcription 
SREBP1 1.011 X Regulation of lipogenesis 
SLC27A1  0.689 X Fatty acid uptake 
PPARγ 0.654 
X X 
Regulation of lipogenesis 
and adipogenesis 
Table 2.4: Obesity-associated genes upregulated in Par-4-/- mouse liver relative 
to Par-4+/+ mouse liver, as determined by RNA-Seq.   
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Fig 2.1: Strategy for constitutive whole-body knockout of Par-4 in mice 
LoxP sites targeting the second exon and locations of genotyping primers '27, 28 
and 30' (A).  Par-4+/+, Par-4+/- and Par-4-/- mice are genotyped by PCR (B).  
Western blotting of various tissues in the Par-4+/+ and Par-4-/- mice, showing the 
reduced Par-4 protein levels (C). 
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Figure 2.2: Adipocyte-specific Par-4 KO (Par-4/AKO) genotyping and 
protein expression 
Genotyping results from fl/fl controls and Par-4/AKO (adipocyte-specific Par-4 
KO) mice (A).  Tissue protein expression of Par-4, demonstrating knockdown 
specificity to adipocytes, as opposed to the stromal-vascular fraction (SVF) or 





Figure 2.3: Chow-fed Par-4 knockout mice are overweight with increased 
fat mass 
Chow-fed whole-body male knockout mice (Par-4-/-) are significantly heavier than 
wild-type control animals (Par-4+/+) by 300 days of age (n=30 per group) (A).  
Growth curves composed from weigh-ins from male mice (n=8 per group) 
demonstrate divergence between 50 and 300 days of age (B).  Also, the Par-4-/-  
mice were found to carry significantly larger gonadal and subcutaneous fat pads 
compared to Par-4+/+ (n=30 mice per group).  EchoMRI readings likewise 
confirmed that the Par-4-/- mice contained a far greater percentage of their mass 
as fat (C).  Comparing weights of major organs (male mice, n=6 per group) 
revealed that the Par-4-/- livers were significantly heavier at 300 days age (D). 
(A,B,C,D) (*) indicates statistical significance (P<0.001) by Student’s t test.   
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Figure 2.4: Par-4-/- mice have enlarged, fatty livers and elevated plasma 
lipids   
The livers of Par-4-/- mice are significantly larger than Par-4+/+ mice by weight 
(n=6 male mice per group) (A).  Oil-red-O staining of livers also showed 
significantly more staining of the Par-4-/-  livers, and thereby more neutral lipid 
accumulation (Scale bars 50μm) (B).  Measuring plasma triglyceride and 
cholesterol levels from male Par-4+/+ mice (n=10) and Par-4-/- mice (n=9) indicate 
the Par-4-/- mice have significantly greater levels of both (C).  Mean+SEM are 
shown for all graphs. 
(A) (**) indicates statistical significance (P<0.001) by Student’s t test. (C) (*) 





          
Figure 2.5: Par-4-/- mice have enlarged adipocytes compared to Par-
4+/+ mice 
Gonadal white adipose tissue collected from 3 and 18 month pairs of male 
Par-4+/+ and Par-4-/- mice show that the Par-4-/-  animals possess visibly 
larger adipocytes at both age groups (scale bars 200μm) (A). This is 
verified by quantification of the cross-sectional area.  Mean+SEM are 
shown. (B). Mean+SD are shown for all graphs (n=8). 





Figure 2.6: Par-4-/- mice have altered adipose hormone levels.  
Obese 12 month old male Par-4-/- mice express  increased leptin (A) and 
reduced Adiponectin (B) in their adipose tissues. Mean+SEM are shown for all 
graphs (n=3 mice per group). 





Figure 2.7: Par-4-/- mice are hyperinsulinemic compared to Par-4+/+ mice.   
OGTT showed only mild elevation of fasting plasma glucose (*) and glucose 
response in male Par-4-/- mice (n=7) compared to male Par-4+/+ mice (n=6) and 
similar responses to  glucose administration (A).   However, the Par-4-/- mice 
displayed steeply elevated insulin at all timepoints (B). Mean±SEM are shown for 
all graphs. 
(A,B) (*) indicates statistical significance (P<0.05) by Student’s t test. 
(B) (**) indicates statistical significance (P<0.01) by Student’s t test.  
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Figure 2.8: Par-4 and SAC overexpression limit weight gain. 
At one year of age, Par-4-overexpressing and SAC-overexpressing mice 
weighed significantly less than GFP-transgenic control mice. Mean+SEM are 
shown for all graphs (n=6 mice per group). 







Figure 2.9: Behavioral and metabolic profiles of Par-4+/+ and Par-4-/- mice 
Metabolic cage recordings of Par-4+/+ and Par-4-/- while fed standard chow 
revealed no difference in caloric intake between the two groups.  However, the 
Par-4+/+ mice proved to be rather more active during the recording period (A).  
Furthermore, Par-4-/- mice displayed elevated resting and total energy 
expenditure and lower 24 hour RER compared to Par-4+/+ (B).  All data was 





Figure 2.10: Par-4 Inhibits adipogenesis in MEFs.   
Par-4-/- MEFs more readily differentiate to adipocytes than Par-4+/+ control cells 
as shown visibly by Oil-Red-O staining (scale bars 200μm) (A) and after 
quantification (B). Data is shown from 5 randomly- selected regions per group.  
Three independent experiments were conducted.  Mean+SEM are shown for the 
graph.   






Figure 2.11: Par-4 inhibits adipogenesis in vitro. 
siRNA knockdown of Par-4 (mouse Par-4 siRNA) in 3T3-L1 cells accelerated 
differentiation to adipocytes compared to control siRNA.  This effect was 
abrogated by co-transfection with mouse PPARγ siRNA (A).  Furthermore, 
combining Par-4 KD with Par-4 overexpression via rat Par-4-containing  
adenovirus (P) counters the effect of Par-4 loss on adipogenesis (B). Infection 
with a control GFP adenovirus (G) had no effect.  (Scale Bars 200µm).  Three 
independent experiments were conducted.  Mean+SEM are shown for all graphs 
from cell counts of five randomly selected visual fields.   
NTC= Non-Transfected/ Transduced Control 
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Figure 2.11: Continued: 
(A,B) (*) indicates statistical significance (P<0.005) by Student’s t test. 







                  
Figure 2.12: Adipocyte - specific Par-4 knockout (Par-4/AKO) mice exhibit 
an obese phenotype. 
Adipocyte-specific Par-4 knockout mice (Par-4/AKO) experience significant 
weight gain starting around 3-4 months- with a 6-month old male pair shown  for 
comparison (A). the 6-month male mice have visibly more adipose tissue, as 
quantified by echo-MRI (n=6 mice per group) (B).  The organ weights were 
similar except for the greatly enlarged livers in the Par-4/AKO mice (C).  
Mean+SEM are shown for all graphs (n=6 mice per group). 
(A,B) (*) indicates statistical significance (P<0.05) by Student’s t test. 





Figure 2.13: Par-4/AKO mice have enlarged adipocytes 
Gonadal WAT from 6 month old male mice was subjected to H&E staining (A) 
and cell size quantified (B) (Scale Bar:200µm) Mean+SEM shown for graph. 




              
Figure 2.14: Par-4/AKO mice have enlarged livers. 
Livers were significantly enlarged in the adipocyte-specific Par-4 knockout mice 
(Par-4/AKO).  Demonstrable increases in size and mass were observed in male, 
6 month old Par-4/AKO mice (n=6 mice per group) (A). Oil red O staining of livers 
also showed significantly more staining of the Par-4/AKO livers, and thereby 
more neutral lipid accumulation (Scale bars 50μm) (B). However, plasma 
triglyceride and cholesterol levels were not significantly different (C).  Mean+SEM 
are shown for all graphs. 





Figure 2.15: Par-4/AKO mice display hyperglycemia and hyperinsulinemia  
OGTT of plasma collected from control and Par-4/AKO mice (male, n=6 mice per 
group) at six months of age revealed hyperglycemia after glucose administration 
(A) and hyperinsulemia (B) in the Par-4/AKO animals.  Mean±SEM are shown for 
all graphs. 
(*) indicates statistical significance (P<0.05) by Student’s t test. 
(**) indicates statistical significance (P<0.01) by Student’s t test. 







Figure 2.16: Behavioral and metabolic profiles of control and Par-4/AKO 
mice 
Par-4/AKO mice (n=5) are recorded as having increased caloric intake but similar 
activity levels compared to controls (n=6) (A).  Further, while there is no 
significant difference in the total energy expenditure between the two groups, 
Par-4/AKO mice were recorded as exhibiting increased resting energy 
expenditure, and increased VCO2/VO2 ratios (B). All data was plotted according 







Figure 2.17: Adipogenesis downregulates Par-4 
Par-4+/+ MEFs differentiated to adipocytes (Adipo) over an 8-10 day period show 
significant downregulation of Par-4 as shown by Western blotting.  Mean+SEM of 
the relative band density of Par-4 relative to GAPDH for three independent 
experiments is shown for graph. 







Figure 2.18: Par-4 is downregulated in obese human subjects. 
Adipose tissue collected from obese (O) and lean human subjects (L) without 
known morbidities show reduced Par-4 RNA levels as demonstrated via qPCR, 
compared to lean human subjects (A).  A similar effect was observed in adipose 
protein expression, as well as plasma Par-4 (B).  Analysis showed that 80% of 
the obese subjects had reduced adipose and plasma levels of Par-4 (C).  
Mean+SEM are shown for all graphs (n=10 adipose and 10 plasma samples per 
group). 





Figure 2.19: Par-4 is downregulated in dietary obese mice. 
Body fat composition data for wild-type C57BL/6 mice given control or HFD for 
16 weeks (n=3 per group) (A). Mice fed a high-fat diet for 16 weeks showed 
reduced Par-4 expression in the adipose tissue, lung and liver, compared to 
control diet (B).  Furthermore, plasma from the animals showed reduced Par-4 
levels in the HFD group (C). 






Figure 2.20: PPARγ1 expression is inversely associated with Par-4 Status 
Western blotting of lysates harvested from Par-4+/+ and Par-4-/- mouse embryonic 
fibroblasts (MEFs) and adult lung primary fibroblasts (Adult FB) showed 
increased expression of PPARγ in the Par-4-/- groups (A). This increase in 
PPARγ is also observed in the livers of Par-4-/- mice (B).  This was also observed 
after stable knockdown of Par-4 (Sh-P4) in A549 and HOP92 cell lines compared 





Figure 2.21: Par-4-/- MEFs show higher levels of PPARγ1 RNA 
qPCR of Par-4+/+ and Par-4-/- MEFs show increased PPARγ1 mRNA levels in the 
Par-4-/- cells.  Mean+SEM are shown for all graphs.  Three independent 
experiments were perfomed. 






Figure 2.22: Par-4 overexpression inhibits PPARγ expression   
3T3-L1 cells were infected with either GFP or GFP-Par-4 adenovirus.  Lysates 
were harvested and subjected to Western blotting (A). Relative band density- 
normalized to GAPDH show reduction of PPARγ1 and γ2 in the Par-4-
overexpressed group (B).  Mean+SEM for three separate experiments are shown 
for graph. 





Figure 2.23: Par-4 inhibits transcription of the PPARγ2 Promoter 
Overlapping Luciferase constructs were generated from the first 3kb of the 
PPARγ2 promoter (A).  These constructs, when transfected into Par-4+/+ and 
Par-4-/- MEFs indicated that Par-4 suppressed activity of the full-length fragment 
(Frag. 1) and the 1.6kb fragment proximal to the ATG site (Frag. 3) (B).  
Mean+SEM for three separate experiments are shown for all graphs. 
(*) indicates statistical significance (P<0.005) by Student’s t test. 




Figure 2.24: PPARγ2 Promoter fragments utilized for luciferase assays  
The 3 KB region upstream of the mouse PPARγ2 ATG site (Frag1) was first 
divided into the partially overlapping 1.6 KB fragments (Frag 2 and Frag 3).  
Based on luciferase data generated by these fragments, Frag 3 was further 
subdivided into fragments 4-8 (A).  Luciferase data from these fragments indicate 
activity of the construct containing Frag. 6 is inhibited by Par-4 (B). Mean+SEM 
for three separate experiments are shown for graph. 





Figure 2.25: Par-4’s effect upon frag.6 is dependent upon nuclear 
localization.  Co-transfection of Frag. 6 with empty pCB6 vector, intact Par-4 or 
Par-4 lacking either of the two nuclear localization sequences (ΔNLS1 or 
ΔNLS2), show that not only does overexpression of Par-4 attenuate the luc 
activity of the Frag.6-containing construct (ᵻ), however, ΔNLS2 co-transfection 
completely abrogates the effect (ᵻᵻ).  Mean+SEM for three separate experiments 
are shown for graph. 
(*) indicates statistical significance (P<0.001) by Student’s t test. 
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Figure 2.26: Chromatin Immunoprecipitation (ChIP) indicates that Par-4 
binds PPARγ2 promoter 
Transfecting NIH 3T3 cells with empty vector, Frag.6 or Frag.7, then pulling down 
with either an anti-Par-4 antibody or anti-IgG antibody show that Par-4 is bound 
to Frag.6-compared to Frag. 7 (A). Performing the same procedure against the 
endogenous NIH 3T3 chromatin (B), verifies Par-4 binding to the PPARγ2 
promoter (†).  Means of three separate experiments shown. 
(*) indicates statistical significance (P<0.05) by Student’s t test. 
(**) indicates statistical significance (P<0.001) by Student’s t test. 
99 
CHAPTER THREE: DISCUSSION AND FUTURE DIRECTIONS 
DISCUSSION 
Par-4 loss promotes obesity and adipogenesis 
Due to the ubiquitous nature of Par-4, we sought to determine whether a 
physiologic role for Par-4 exists outside of tumor-suppressor activity.  Overall, 
this study has revealed a significant physiologic function for Par-4, which is 
independent of its known tumor-suppressor function.  From this series of 
experiments, we have determined that Par-4 inhibits adipogenesis and adipose 
lipid storage.  This overall finding has been replicated utilizing cell culture 
models, and long-duration in vivo studies.  These in vivo models included 
comparisons of constitutive whole-body Par-4 knockout mice against controls 
and comparing adipocyte-specific Par-4 knockout mice against controls.  We 
have found evidence that Par-4 loss promotes adipogenesis and hypertrophy of 
existing adipocytes, resulting in marked fat accumulation and subsequent obesity 
of the animals.   
In whole-body Par-4 knockout animals, expression of the adipose hormones 
leptin and adiponectin are affected (i.e.: adiponectin decreased and leptin 
increased in the knockout animals).  These observations are typical in obese 
subjects (Arita et al., 1999) as paradoxically, adiponectin is downregulated in 
obese subjects through hypermethylation of the adiponectin promoter (A. Y. Kim 
et al., 2015).  Furthermore, while leptin is usually proportional to adipodosity as a 
compensatory mechanism by increasing feelings of satiety and thereby reducing 
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feeding behavior, there is observed a loss of leptin sensitivity at the 
hypothalamus in chronic obesity(Levin & Dunn-Meynell, 2002).  So while the 
observed trends in leptin and adiponectin expression are consistent with high 
adipodosity, they are likely not causative in this context as the weight differential 
was already present at the time of sample collection.  Also, prior to the observed 
weight gain, metabolic cage data indicated no difference in food intake. 
Metabolic cage data on the whole-body Par-4-/- mice indicated that, although 
there was increased activity recorded in the Par-4+/+ animals, the effect 
disappears in the Par-4/AKO animals compared to controls.  While feeding 
behavior is evidently not a factor in the Par-4-/- animals, the Par-4/AKO mice 
showed increased caloric intake, although the trendlines have rather different 
trajectories.  It would be useful to examine leptin expression in these two 
populations to observe whether any difference exists for this marker prior to 
weight gain.  Furthermore, energy expenditure would not appear to account for 
the obese phenotype as the Par-4-/- mice showed increased total energy 
expenditure and the Par-4/AKO mice showed no difference compared to 
respective control animals.  The 24hr RER for both Par-4-/- and Par-4/AKO mice 
is however elevated compared to controls.  This indicates that although all 
populations are using a mix of carbohydrate and fat for energy (RER between 
0.85-0.95)(Shmidt-Neilson, 1997), the Par-4-/- and Par-4/AKO mice are biased 
towards carbohydrate rather than fat utilization.  This could be accounted for by 
the increased expression of genes capable of inhibiting β-oxidation, as shown 
below.   
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RNA seq data showed that Acetyl-CoA Carboxylase 1 and 2 (ACC1 and ACC2) 
levels are both found to be upregulated in Par-4-/- livers.  ACC1 increases fatty 
acid synthesis, whereas ACC2 inhibits β-oxidation; both enzymes are also found 
in adipocytes as well as the liver and other peripheral tissues (Wakil & Abu-
Elheiga, 2009).  Upregulation of both would appear to bias the system towards 
accumulation of fatty acids.  Another possibility is that the elevated levels of G-
protein signaling regulator RGS-16 found in the Par-4-/- mouse livers might be 
inhibiting fatty acid oxidation (Pashkov et al., 2011).  However, given the current 
lack of data regarding the function of RGS-16 in adipose tissue, this would not 
explain the obesity and metabolic phenotype observed in the Par-4/AKO mice.  
Further investigation might be necessary, perhaps looking at differential 
expression of CPT-1 or other mitochondrial enzymes required for β-oxidation.  
Increased expression of the fatty acid transporters CD36 and SLC27A1 in the 
Par-4-/- mice might also indicate a phenotype biased towards lipid accumulation 
in the adipocytes.  Knockout of CD36 in mice prevents HFD- induced obesity and 
also attenuates inflammatory activity (Cai, Wang, Ji, Meyer, & van der 
Westhuyzen, 2012). 
We have also found that the livers are enlarged and accumulate fat in both 
whole-body knockout and adipocyte-specific Par-4 knockout mice.  However, we 
note this has been in association with hyperinsulinemia, which was observed in 
the whole body and adipocyte-specific knockouts.  While the literature is not 
always in agreement as to the sequence of events, the literature notes that the 
liver can uptake the increased FFAs released from adipose tissue in response to 
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insulin.  As was mentioned in the Introduction chapter, hyperinsulinemia is 
known to stimulate de novo lipogenesis (DNL).  The evidence shows that if Par-4 
is directly enhancing DNL, this behavior might be limited to the adipose tissue. 
However, further investigation might be warranted- utilizing a liver-specific Par-4 
KO mouse (generated by crossing Par-4fl/fl mice with albumin-Cre mice).   
Both the Par-4-/- and Par-4/AKO mice displayed acute hyperinsulinemia after 
fasting and at all timepoints in the oral glucose tolerance test compared to 
controls.  It has been demonstrated that increasing PPARγ activity in the 
pancreas promotes insulin secretion (H.-S. Kim et al., 2013).  However, as this 
occurred in the adipose specific knockout mice as well, we consider this to be a 
secondary effect of the adipodosity.  We are currently investigating whether the 
experimental mice demonstrate adipose macrophage infiltration and 
inflammatory markers which would promote this phenomenon.   
A potential contradiction of PPARγ’s role in the Par-4 loss situation is that PPARγ 
ordinarily improves glucose homeostasis by stimulating glucose uptake.  It may 
be noted that the plasma glucose levels in the Par4-/- mice are barely higher than 
Par-4+/+ mice.  However, the plasma glucose after glucose administration is very 
much higher in the Par-4/AKO mice.  Perhaps elevated PPARγ in the peripheral 
tissues in the Par-4-/- mice is able to compensate somewhat for the 
hyperinsulinemia, whereas this is less likely in the Par-4/AKO model (less lean 
tissue).  Performing OGTT/ insulin tests at earlier timepoints might shed light on 
this model. 
103 
Mechanistically, we have identified a number of obesity-associated genes which 
are regulated by Par-4 status.  These include factors which are responsible for 
the synthesis and elongation of fatty acids (ACC1, SCD1, ELOVL6, FASN and 
Lipin1).  These factors are also expressed in adipose tissue and adipocytes 
(Berndt et al., 2007; Matsuzaka & Shimano, 2009; Wakil & Abu-Elheiga, 2009; 
Yew Tan et al., 2016; P. Zhang, O’Loughlin, Brindley, & Reue, 2008).  Additional 
upregulated factors which have been found in adipose tissue are involved in 
fatty-acid uptake (CD36, SLC27A1) and transport (FABP) (Bonen, Tandon, 
Glatz, Luiken, & Heigenhauser, 2006; Furuhashi & Hotamisligil, 2008; Martin et 
al., 2000).  Additionally upregulated are factors which inhibit lipid β-oxidation 
(ACC-2, RGS16)-also found in adipocytes (Oh et al., 2005; “RGS-16 gene 
(Genecards),” n.d.).  Since it is possible to demonstrate the obese phenotype 
generated by Par-4 loss solely in the adipose tissue, with associated steatosis 
and hyperinsulinemia, we believe that the effects on those organ systems 
(hepatic and pancreatic) are secondary to the adipose expansion.  However, they 
could contribute to the phenotype of the Par-4-/- mice due to the livers role in 
lipogenesis.  However, as all the factors described above are also found in 
adipose tissue, it would appear that enhanced lipogenesis and reduced β-
oxidation in the adipose tissue have a role in the obese phenotype observed in 
the Par-4-/- and Par-4/AKO mice. 
Critically, we have identified the transcription factor and adipogenic master 
regulator PPARγ as being regulated by Par-4 at the promoter level, and believe it 
to be the primary regulatory element through which Par-4 influences 
104 
adipogenesis.  The supporting data has been gathered from Western blotting, 
qPCR, luciferase-based reporter assays and ChIP.  These demonstrate that Par-
4 influence the transcription and expression of PPARγ1 and 2, that nuclear entry 
of Par-4 is required for its influence upon PPARγ2 promoter activity, and finally 
that Par-4 is capable of directly or indirectly binding to the chromatin of the 
PPARγ2 promoter.  Together, the data indicate that nuclear Par-4 binds to a 
corepressor complex at the promoter for PPARγ2, thereby attenuating its 
transcription and consequently reducing the expression of downstream genes, 
such as those required for adipogenesis. (Figure 3.1). 
Par-4 is downregulated by adipogenesis and obesity 
Complimentary to our findings that Par-4 can inhibit adipogenesis and obesity, 
we have discovered that in vitro adipocyte differentiation results in the 
downregulation of Par-4.  Follow-up in vivo studies have demonstrated that 
obesity is not only capable of downregulating Par-4 expression in various tissues, 
but also reduce levels of circulating Par-4 in mouse and human subjects.  These 
findings have interesting implications for cancer studies.  Obesity has already 
been associated with increased incidence and mortality of several types of 
cancer (Kelesidis et al., 2006).There are several proposed mechanisms for this 
relationship.  However because intracellular and extracellular Par-4 has been 
previously found to selectively induce apoptosis in tumor cells (Burikhanov et al., 
2009; Nadia El-Guendy et al., 2003), our observed Par-4 downregulation may be 
a contributing factor in this milleau.  
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FUTURE DIRECTIONS 
Obesity and metabolic disease represent complicated phenomena, with multiple 
known causes and intermediate factors.  Although our experiments detailed 
herein have demonstrated that Par-4 status inhibits adipogenesis and fat 
accumulation, our RNAseq data indicates Par-4 loss increases transcription of a 
number of genes responsible for controlling lipid metabolism and transport which 
are not demonstrated PPARγ transcriptional targets.  Examples include Lipin-1, 
ELOVL-6 and RGS-16.  It would be reasonable to assume that although PPARγ 
is the master adipogenic regulator, that it is not the sole relevant transcriptional 
target for Par-4.  This opens many possible avenues for investigation.  
Another significant aspect of our model recommends further investigation.  While 
we have found direct evidence of Par-4 interacting with the promoter sequence 
for PPARγ2, these experiments have not yet been extended to the promoter 
sequences for PPARγ1.  Western blotting and qPCR experiments have shown 
that protein expression and transcription of PPARγ1 are also affected by Par-4 
status.  Both isoforms have some common transcription factors like CREB, FOX-
O1 and C/EBPα/β, so it stands to reason that Par-4 could influence both 
isoforms.  Due to the significance of PPARγ1 in regulating insulin sensitivity and 
metabolism in many tissues, pinpointing Par-4’s role would enhance our 
understanding of this regulatory pathway. 
As has been previously mentioned, although Par-4 possesses a leucine zipper 
domain, it lacks flanking basic amino acid residues which would otherwise allow 
106 
direct Par-4-DNA binding.  Since we have shown Par-4 binding to the chromatin 
of the PPARγ2 promoter, this indicates that Par-4 must have a protein binding 
partner within that region.  Par-4 has multiple domains capable of protein-protein 
interactions: the LZ is already known to bind to WT-1, and PKCζ; further, a VASA 
domain sequence within the Par-4 N-terminal region has recently been found to 
bind the E3 ubiquitin ligase Fbxo45 (Hebbar et al., 2017) and the SAC domain 
can bind GRP78.  Essentially, further studies would be required to determine 
which domain (or portion thereof) of Par-4 binds to our hypothesized 
transcriptional repressor complex.  Furthermore, the binding partner(s) of Par-4 
are yet to be identified.  The JASPAR database identifies many putative 
transcription factor binding sites within the Frag. 6 sequence which would need to 
be individually investigated.  
Furthermore, Par-4 is clearly downregulated during adipogenesis in vitro and in 
obese mouse and human subjects in vivo.  The actual underlying mechanism is 
however unclear at this juncture.  Preliminary trials (data not shown), to 
determine the effects of individual components of the adipogenesis differentiation 
media did not show any individual component to be capable of replicating the 
Par-4 downregulation seen in the complete differentiation media.  We currently 
conclude that the effect of the media components must be an additive or 
synergistic one and that further investigation is warranted.  Likewise: regarding 
the reduced in vivo tissue expression and plasma levels of Par-4, there are 
insufficient data to demonstrate the time-course comparing weight gain and Par-
4 downregulation.  While human studies would be impractical, continued and 
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thorough dietary-obese mouse time-course studies may better illustrate the 
relationship between weight gain and Par-4 expression.   
Another potential mechanism underlying reduced plasma Par-4 levels in obese 
subjects, might be due to altered expression of secretory proteins in the dietary 
obese mice.  Rab8b is a GTPase found to be requisite for vesicular secretion of 
Par-4 into the extracellular environment (Burikhanov et al., 2017).  Ravshan 
Burikhanov was able to find that Rab8B is downregulated in the adipose tissue of 
our dietary obese mouse subjects, but this was not replicated in liver or lung 
lysates (Figure 3.2).  
Another experimental direction that we wish to undertake would be the 
investigation of Par-4-mediated therapies for the amelioration of obesity or other 
metabolic disorders.  Secretagogues for Par-4, such as chloroquine and 
Arylquin-1 could be tested for their ability to affect adipogenesis and lipogenesis 
and whether this effect is Par-4 dependent, as opposed to autophagy dependent 
in the case of chloroquine.  Also, given the role of inflammation in obesity, and 
upon the liver, we would like to investigate whether Par-4 loss promotes 
inflammation or macrophage infiltration into the adipose, liver or pancreatic 
tissues. 
SUMMARY
I have identified a novel physiologic regulatory role for par-4, namely regulation 
of adipogenesis and lipogenesis, which is capable of preventing obesity in chow-
fed mice.  These findings have been replicated in in vitro and in vivo models.  
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This action has been attributed to a number of obesity-related genes, particularly 
through discovery of a transcriptional repressor function of Par-4 at the promoter 
of PPARγ2.  It further appears that Par-4 downregulation is a requisite step for 
adipogenic activity.  We therefore believe that as Par-4 is downregulated, 
PPARγ2 will be upregulated and fibroblasts will become more prone to 
differentiation into adipocytes and promoting lipid storage. 
In addition, we have found evidence that dietary induced obesity can lead to 
downregulation of Par-4 in multiple tissues in mice and humans as well as 
reduced circulating levels of Par-4 in both species.  As intracellular and 
extracellular Par-4 are both capable of attenuating tumorigenesis and metastasis, 
this finding reveals a novel mechanism for obesity-associated tumorigenesis.   
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Figure 3.1: Proposed model for Par-4 regulation of PPARγ transcription.  
Cytoplasmic Par-4 is translocated to the nucleus, whereupon it associates with a 
currently unidentified DNA binding protein or proteins at the PPARγ promoter, 
thereby inhibiting transcription of PPARγ. 
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Figure 3.2: Adipose RAB8B expression downregulated under HFD  
Western blotting indicated that RAB8B is downregulated in the adipose tissue of 
dietary obese mice.  We wish to investigate whether reduced secretion of Par-4 
might account for reduced plasma Par-4 levels observed in dietary obese mice. 
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